



# A Comprehensive Review of Manifestations of Novel Coronaviruses in the Context of Deadly COVID-19 Global Pandemic



Aishwarya Gulati, MD<sup>1</sup>, Corbin Pomeranz, MD<sup>1</sup>, Zahra Qamar, MD<sup>2</sup>,  
Stephanie Thomas, MD<sup>3</sup>, Daniel Frisch, MD<sup>2</sup>, Gautam George, MD<sup>2,4</sup>,  
Ross Summer, MD<sup>2,4</sup>, Joseph DeSimone, MD<sup>2</sup> and  
Baskaran Sundaram, MD<sup>1</sup>

Departments of <sup>1</sup> Radiology, <sup>2</sup> Medicine, <sup>3</sup> Obstetrics and Gynecology and the  
<sup>4</sup> Jane and Leonard Korman Respiratory Institute, Thomas Jefferson University,  
Philadelphia, Pennsylvania

## ABSTRACT

Since December 2019, the global pandemic caused by the highly infectious novel coronavirus 2019-nCoV (COVID-19) has been rapidly spreading. As of April 2020, the outbreak has spread to over 210 countries, with over 2,400,000 confirmed cases and over 170,000 deaths.<sup>1</sup> COVID-19 causes a severe pneumonia characterized by fever, cough and shortness of breath. Similar coronavirus outbreaks have occurred in the past causing severe pneumonia like COVID-19, most recently, severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV). However, over time, SARS-CoV and MERS-CoV were shown to cause extrapulmonary signs and symptoms including hepatitis, acute renal failure, encephalitis, myositis and gastroenteritis. Similarly, sporadic reports of COVID-19 related extrapulmonary manifestations emerge. Unfortunately, there is no comprehensive summary of the multiorgan manifestations of COVID-19, making it difficult for clinicians to quickly educate themselves about this highly contagious and deadly pathogen. What is more, is that SARS-CoV and MERS-CoV are the closest humanity has come to combating something similar to COVID-19, however, there exists no comparison between the manifestations of any of these novel coronaviruses. In this review, we summarize the current knowledge of the manifestations of the novel coronaviruses SARS-CoV, MERS-CoV and COVID-19, with a particular focus on the latter, and highlight their differences and similarities.

**Key Indexing Terms:** Severe acute respiratory syndrome coronavirus; Middle east respiratory syndrome coronavirus; COVID-19; Novel coronavirus. [*Am J Med Sci* 2020;360(1):5–34.]

## INTRODUCTION

The current global pandemic due to the highly contagious COVID-19 infection is rapidly spreading in many countries with a high number of deaths. Many communities and countries have enforced restrictions, permitting only essential activities. Health systems around the globe are currently preparing to manage the surge of the influx of critically ill patients. During this phase, care providers, administrators and policymakers work in concert to understand and combat this deadly pandemic. The current knowledge about COVID-19 is limited but rapidly evolving. During this outbreak, the medical community used evidence gleaned from past outbreaks of SARS-CoV and MERS-CoV to predict COVID-19's behavior, clinical presentation and treatment. In addition, coronaviruses (CoV) are known to cause signs and symptoms of multiorgan system damage, many of which are subtle and can go unnoticed by

trained medical professionals. Furthermore, frontline healthcare personnel lack a comprehensive review of the numerous clinical pulmonary and extrapulmonary manifestations of deadly CoVs making self-education time consuming.

We have attempted to summarize the manifestations of COVID-19 and other CoVs in many organs with the goal of consolidating knowledge to address the current pandemic. We hope that this review will provide information that would help to manage patients, evaluate manifestations in different organs, predict complications and prognosis, allocate resources in the appropriate domains, and provide opportunities for research.

## METHODS

We searched the published literature for multiple combinations of different organs, and names for

infectious conditions of those organs and novel CoVs. We only included articles written in the English language and published after 2002. We included both animal and human research studies. The search methodology resulted in nearly 2000 articles. During the further review, we limited the number of articles by eliminating articles that lacked direct relevance. We populated tables with disease manifestations in various organs (Tables 1-8).

## **PATHOGENS**

CoVs are a large family of single-stranded RNA viruses that infect humans primarily through droplets and fomites. Before December 2019, there were 6 known human CoVs, including the alpha-CoVs, HCoV-NL63 and HCoV-229E, and the beta-CoVs, HCoV-OC43, HCoV-HKU1, severe acute respiratory syndrome-CoV (SARS-CoV) and middle east respiratory syndrome (MERS-CoV).<sup>2</sup> The recently identified COVID-19 is a beta-CoV that infects both humans and animals. All 3 of these novel viruses (SARS-CoV, MERS-CoV and COVID-19) originate from zoonotic transmission. Bats may have served as the source of SARS-CoV and COVID-19 based on sequence similarity with bat CoVs. Camels are suspected to have been the zoonotic host for transmission of MERS-CoV.

The SARS-CoV outbreak spanned from 2002 to 2003 infecting 8,098, causing 774 deaths resulting in a 5-10% mortality and a 43% mortality in the elderly.<sup>3,4</sup> The MERS-CoV outbreak was first reported in Saudi Arabia in 2012.<sup>4</sup> It then spread to Europe, Asia, Africa and North America and infected 2,494 people, causing 858 death.<sup>5</sup> The MERS-CoV caused severe pneumonia with an intensive care unit (ICU) admission rate of 40-50% and an in-hospital ICU death rate of 75%.<sup>6,7</sup> In December 2019, the city of Wuhan in Hubei Province, China, reported a small outbreak of a novel coronavirus, COVID-19. The fatality rate is highest in adults  $\geq 85$  years old (10-27%), followed by 65-84 years (3-11%) with 50% of ICU admission among persons  $\geq 65$  years. The World Health Organization declared COVID-19 as a pandemic on March 11, 2020.

## **PULMONARY MANIFESTATIONS**

### **SARS-CoV**

Patients infected with SARS-CoV initially had features of atypical pneumonia. Cough was a common presenting symptom in up to 74% of patients<sup>8-10</sup> (Table 1). Other symptoms suggestive of an upper respiratory tract infection (e.g., rhinitis) were less frequent.<sup>11</sup> Approximately 50% of patients developed hypoxia during hospitalization, and up to 26% progressed to acute respiratory distress syndrome (ARDS) requiring mechanical ventilation.<sup>8,12</sup> The elderly and patients with multiple comorbidities had particularly high (more than 15.7%) mortality.<sup>12,13</sup> Unilateral, focal, peripheral areas

of consolidations on imaging were identified in upwards of 78% of patients.<sup>10</sup> Histopathology revealed diffuse serous, fibrinous and hemorrhagic inflammation. SARS-CoV RNA has been detected in type II alveolar cells, interstitial cells and bronchial epithelial cells, suggesting infection of both proximal and distal epithelium of the lung.<sup>13</sup> Most patients received antibacterial antibiotics, with or without the use of ribavirin and corticosteroids.<sup>9-11</sup>

Angiotensin-converting enzyme 2 (ACE2) serves as a functional receptor to SARS-CoV.<sup>13,14</sup> SARS-CoV also disrupts the urokinase pathway, which controls fibrin levels through extracellular remodeling, and is associated with pulmonary hemorrhage and fibrosis.<sup>15</sup> SARS-CoV also triggers the production of high levels of proinflammatory cytokines contributing to excessive inflammation in the lungs. Hence, anticytokine and chemokine immunotherapy may be effective for minimizing collateral damage.<sup>12</sup>

### **MERS-CoV**

Common presenting symptoms of MERS include dyspnea in up to 92% and cough in 83% of patients<sup>16,17</sup> (Table 1). In a study including 47 patients, all patients presented with an abnormal chest radiograph, 89% needed ICU admissions, and 72% required mechanical ventilation. The case fatality rate was 60%, and the rate increased with age.<sup>16</sup> Most patients received antibiotics, and a small minority received corticosteroids, ribavirin and intravenous immunoglobulin.<sup>17</sup> In a small case series, antiviral therapy was not beneficial.<sup>18</sup> MERS-CoV also induces overexpression of inflammatory cytokines and/or chemokines.<sup>19</sup>

### **COVID-19**

A dry cough is a common symptom in COVID-19 infection, present in up to 68% of patients<sup>20</sup> (Table 1). Sore throat and sputum production are uncommon (5% or less).<sup>21</sup> The presence of dyspnea is predictive of ICU admission.<sup>21</sup> In early descriptions of hospitalized patients in China, all patients had an abnormal chest computed tomography.<sup>20,22</sup> Ground glass opacities are common (56%), followed by consolidation and interstitial abnormalities.<sup>21</sup> In a large Chinese study, the course was complicated by ARDS in 3.4% patients, 6.1% required mechanical ventilation, and the case fatality rate was 1.4-2.1%.<sup>21</sup> Other studies noted a higher incidence of ARDS among hospitalized patients (29%), and higher mortality (15%).<sup>20,22</sup> Respiratory failure tends to have a delayed onset, occurring approximately 1 week after the onset of symptoms. Patients with critical illness were on average older (median age 66 versus [vs.] 51 noncritically patients) and had more comorbidities.<sup>20</sup> Patients who received invasive mechanical ventilatory support were more likely to be male and obese.<sup>23</sup> Histopathology of the lung shows diffuse alveolar damage, denuded

**Table 1.** Pulmonary manifestations of SARS-CoV, MERS-CoV and COVID-19.

<b>SARS (only studies with large study population included)</b>				
Study	Lee et al (2003) N = 138, confirmed cases Retrospective study	Lang et al (2003) N = 3, confirmed cases Clinicopathologic study	Liu et al (2004) N = 53, confirmed cases Retrospective study	Peiris et al (2003) N = 75, confirmed cases Prospective study
Clinical features	<ul style="list-style-type: none"> <li>• Preexisting chronic pulmonary disease (2.1%)</li> <li>• Fever (100%)</li> <li>• Cough (57.3%)</li> <li>• Sputum (29%)</li> <li>• Sore throat (23.2%) Coryza (22.5%)</li> <li>• Inspiratory crackles</li> </ul>	<ul style="list-style-type: none"> <li>• Fever (3/3)</li> <li>• Dyspnea (3/3)</li> <li>• Mildly productive cough (1/3)</li> <li>• Death within 9-15 days of illness</li> </ul>	<ul style="list-style-type: none"> <li>• Fever (98%)</li> <li>• Cough (68% on admission to isolation, 74% after hospitalization, 26% productive)</li> </ul> <p>4.5 ± 1.9 days after fever onset</p> <ul style="list-style-type: none"> <li>• Dyspnea (40% on admission to isolation)</li> <li>• O<sub>2</sub> saturation &lt;90% on room air (51% on hospitalization, 11% on admission to isolation)</li> </ul>	<ul style="list-style-type: none"> <li>• Fever (100%), recurred in 85% at mean 8.9 days</li> <li>• Cough (29%)</li> <li>• Spontaneous pneumomediastinum (12%) during follow-up</li> <li>• Sore throat (11%)</li> <li>• Shortness of breath (4%)</li> <li>• O<sub>2</sub> saturation &lt; 90% on room air (44mean 9.1 days after symptom onset)</li> </ul>
Key findings on investigations	<p>CXR</p> <ul style="list-style-type: none"> <li>• Consolidation (78.3% at fever onset, eventually 100%)</li> <li>• 54.6% unilateral, focal</li> <li>• 45.4% multifocal or bilateral</li> <li>• Peripheral zone predominant</li> </ul> <p>CT</p> <ul style="list-style-type: none"> <li>• Progression of chest CT infiltrates 7-10 days after admission, resolution with treatment</li> <li>• Ill-defined peripheral GGO, usually subpleural</li> </ul>	<ul style="list-style-type: none"> <li>• Leukopenia (2/3)</li> <li>• Lymphopenia (2/3)</li> <li>• CXR: Bilateral interstitial infiltrates</li> </ul>	<ul style="list-style-type: none"> <li>• Abnormal CXR (59% on admission, 98% anytime)</li> <li>• 63% patients – first unifocal infiltrates at 4.5 ± 2.1 days</li> <li>• 37% patients - started as multifocal infiltrates at 5.8 ± 1.3 days after fever onset</li> </ul>	<p>Initial CXR abnormal: 71%</p> <ul style="list-style-type: none"> <li>• One lung zone: 49%</li> <li>• Multizonal: 21%</li> </ul> <p>Chest CT abnormal (55% of 33)</p> <ul style="list-style-type: none"> <li>• One lobe: 55%</li> <li>• Multilobar: 46%</li> <li>• Focal ground-glass opacification: 24%</li> <li>• Consolidation: 36%</li> <li>• Both: 39%</li> </ul> <p>Radiologic worsening in 80% at mean 7.4 days</p>
Histopathology	<ul style="list-style-type: none"> <li>• Gross: Lung consolidation</li> <li>• Early phase: Pulmonary edema with hyaline membrane formation</li> <li>• Organizing phase: Cellular fibromyxoid organizing exudates in alveoli</li> <li>• Scanty lymphocytic interstitial infiltrate</li> <li>• Vacuolated and multinucleated pneumocytes</li> <li>• Viral inclusions not detected.</li> </ul>	<ul style="list-style-type: none"> <li>• Gross: Diffuse hemorrhage on lung surface</li> <li>• Serous, fibrinous and hemorrhagic inflammation in alveoli with desquamation of pneumocytes and hyaline-membrane formation</li> <li>• Capillary engorgement and capillary microthrombosis, thromboemboli in bronchial arterioles</li> <li>• Hemorrhagic necrosis lymphocyte depletion in lymph nodes and spleen</li> <li>• Viral RNA detected in type II alveolar cells, interstitial cells and bronchiolar epithelial cells</li> </ul>	N/A	N/A

(continued on next page)

Table 1. (continued)

<b>SARS (only studies with large study population included)</b>				
Key study findings and message	<ul style="list-style-type: none"> <li>• 23.2% ICU admission, at day 6 (mean)</li> <li>• 13.8% mechanical ventilation rate</li> <li>• 3.6% crude mortality rate</li> <li>• ICU patients more likely to be of older age (<math>P = 0.009</math>)</li> </ul>	Severe immunological damage to lung tissue causes clinical features	<ul style="list-style-type: none"> <li>• Fever most common and earliest symptom</li> <li>• 23% mechanical ventilation rate</li> </ul>	<ul style="list-style-type: none"> <li>• 83.33% of patients with GGO developed ARDS</li> <li>• 20% mechanical ventilation</li> <li>• 17% ICU admission</li> <li>• Recurrence of fever (univariate) and age (multivariate) risk factors for ARDS and ICU admission</li> </ul>
<b>MERS</b>				
Study	Assiri et al (2013) $N = 47$ , confirmed cases Retrospective study	Arabi et al (2014) $N = 12$ , (11 confirmed cases, 1 probable) Case series	Al-Abdley et al (2019) $N = 33$ , confirmed cases Retrospective study	Almekhlafi et al (2016) $N = 31$ , confirmed cases Retrospective study
Clinical features	<ul style="list-style-type: none"> <li>• Preexisting chronic lung disease (26%)</li> <li>• Smokers (23%)</li> <li>• Fever (98%)</li> <li>• Cough (83%)</li> <li>• Dry (47%)</li> <li>• Productive (36%)</li> <li>• Dyspnea (72%)</li> <li>• Sore throat (21%)</li> <li>• Rhinorrhea (4%)</li> </ul>	<ul style="list-style-type: none"> <li>• Preexisting chronic lung disease (8%)</li> <li>• Dyspnea (92%)</li> <li>• Cough (83%)</li> <li>• Fever (67%)</li> <li>• Wheezing (17%)</li> <li>• Productive cough (17%)</li> <li>• Rhinorrhea (8%)</li> <li>• Hemoptysis (8%)</li> <li>• Sore throat (8%)</li> </ul>	<ul style="list-style-type: none"> <li>• Preexisting chronic lung disease (12%)</li> <li>• Fever (75.7%)</li> <li>• Cough (72%)</li> <li>• Dyspnea (59%)</li> <li>• Sore throat (12%)</li> <li>Rhinorrhea (9%)</li> </ul>	<ul style="list-style-type: none"> <li>• Cough (100%)</li> <li>• Tachypnea (100%)</li> <li>• Fever (87.1%)</li> <li>• Sore throat (25.8%)</li> <li>• Crackles (93.5 %)</li> <li>Rhonchi (32.3 %)</li> </ul>
Key findings on investigations	CXR abnormality (100%) – ARDS pattern	CXR, CT: lobular to bilateral extensive ARDS pattern	N/A	CXR abnormality (96.4%)
Key study findings and message	<ul style="list-style-type: none"> <li>• 89% ICU admission</li> <li>• 72% mechanical ventilation</li> <li>• 60% case fatality rate</li> </ul>	100% invasive mechanical ventilation, mean duration 100 days	<ul style="list-style-type: none"> <li>• Dyspnea before admission was associated with a more severe outcome (<math>P &lt; 0.001</math>)</li> <li>Prolonged MERS-CoV detection in URT in diabetics (<math>P = 0.049</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• 87.1 % invasive mechanical ventilation (87.1%)</li> <li>• 74.2% overall ICU mortality rate</li> <li>• Mortality in ICU associated with older age, severe disease and organ failure.</li> </ul>
<b>COVID-19</b>				
Study	Huang et al (2020) $N = 41$ , confirmed cases Retrospective study	Wang et al (2020) $N = 138$ , confirmed cases Retrospective study	Guan et al (2020) $N = 1099$ , confirmed cases Retrospective study	Zhang et al (2020) $N = 1$ , confirmed cases Clinicopathologic study
Clinical features	<ul style="list-style-type: none"> <li>• Smoker (7%)</li> <li>• Preexisting COPD (2%)</li> <li>• Fever 98%</li> <li>• Dry cough (76%)</li> <li>• Dyspnea (55%), mean 8 days after onset</li> <li>• Sputum (28%)</li> </ul>	<ul style="list-style-type: none"> <li>• Preexisting COPD (2.9%)</li> <li>• Fever 98.6%</li> <li>• Dry cough (59.4)</li> <li>• Sputum (26.8%)</li> <li>• Dyspnea, mean 5 days after onset</li> <li>• ARDS (19.6%), mean 8 days after onset</li> </ul>	<ul style="list-style-type: none"> <li>• Preexisting chronic pulmonary disease (1.1%)</li> <li>• Fever (43.8% on admission, 88.7% during hospitalization)</li> <li>• Cough (67.8%)</li> <li>• Sputum (33.7%)</li> <li>• Sore throat (13.9%)</li> </ul>	<ul style="list-style-type: none"> <li>• Fever</li> <li>• Cough</li> <li>• ARDS requiring mechanical ventilation within 1 week</li> </ul>

(continued on next page)

**Table 1. (continued)**

COVID-19				
	<ul style="list-style-type: none"> <li>• Hemoptysis (5%)</li> <li>• ARDS (29%), mean 9 days after onset</li> <li>• ↑RR &gt;24/min (29%)</li> </ul>		<ul style="list-style-type: none"> <li>• Nasal congestion (4.8%)</li> <li>• Hemoptysis (0.9%)</li> <li>• ARDS (3.4%)</li> <li>• 1.4% case fatality rate</li> <li>• 4 days median incubation period</li> </ul>	
Key findings on investigations	Abnormal chest CT (100%); (98% bilateral)	<ul style="list-style-type: none"> <li>• ↓PaO<sub>2</sub></li> <li>• ↓PaO<sub>2</sub>:FIO<sub>2</sub></li> </ul>	<ul style="list-style-type: none"> <li>• Abnormal CXR (59.1%)</li> <li>• Abnormal Chest CT (86.2%)</li> <li>• Ground glass opacity most common (56.4%)</li> <li>• No lung imaging findings in 17.9% patients with nonsevere disease and in 2.9% with severe disease</li> </ul>	CT: Patchy bilateral ground glass opacities
Histopathology	N/A	N/A	N/A	<ul style="list-style-type: none"> <li>• Diffuse alveolar damage with organizing changes of fibrous plugs, with interstitial fibrosis and chronic inflammatory infiltrates</li> <li>• Denuded alveolar lining with pneumocyte type II hyperplasia</li> <li>• Virus detected on alveolar epithelial cells including desquamated cells, not in blood vessels</li> </ul>
Key study findings and message	<ul style="list-style-type: none"> <li>• ICU patients had more areas of consolidation</li> <li>• 10% mechanical ventilation rate, mean 10.5 days after onset</li> <li>• 5% ECMO rate</li> </ul>	<ul style="list-style-type: none"> <li>• High-flow O<sub>2</sub> therapy in 11.1% ICU patients, noninvasive ventilation in 41.7%, and invasive ventilation in 47.2%</li> <li>• Older patients (<i>P</i> &lt; 0.001), patients with more comorbidities, dyspnea and anorexia more likely to require ICU care</li> <li>• Mortality: 4.3%</li> </ul>	<ul style="list-style-type: none"> <li>• Mechanical ventilation needed (6.1%)</li> <li>• Radiographic abnormalities often absent</li> </ul>	Histopathologic findings consistent with diffuse alveolar damage
ARDS, acute respiratory distress syndrome; CXR, chest x-ray; ECMO, extracorporeal membrane oxygenation; GGO, ground glass opacities; ICU, intensive care unit; MERS-CoV, middle east respiratory syndrome coronavirus; RR, respiratory rate; SARS-COV, severe acute respiratory syndrome coronavirus; URT, upper respiratory tract.				

alveolar lining cells and interstitial fibrosis.<sup>24</sup> There is also evidence of a higher incidence of thromboembolism in COVID-19 patients and an association between elevated D-dimer levels and mortality.<sup>25</sup> Additionally, preliminary evidence suggests that heparin use may result in lower 28-day mortality rates when compared to in COVID-19 patients not receiving this therapy.<sup>26</sup>

Currently, it is speculated that respiratory compromise due to COVID-19 is driven by cytokine-mediated injury of the lung and that interventions to reduce the activity of specific inflammatory mediators may improve outcomes.<sup>27,28</sup> COVID-19 also uses ACE2 receptor to enter into cells so therapies targeting this receptor may serve as a potential treatment option.<sup>29-32</sup> There is no standard of care for the prevention or treatment of respiratory compromise in COVID-19 yet. Medications including glucocorticoids, IL-6 antagonists, Janus kinase inhibitors, antivirals and chloroquine and/or hydroxychloroquine are currently being studied as possible therapeutic options.<sup>33</sup>

## CARDIOVASCULAR MANIFESTATIONS

### SARS-CoV

Patients may present with cardiac arrhythmia, failure and myocarditis<sup>34-37</sup> (Table 1). A study on 121 hospitalized SARS-CoV patients found that tachycardia was the most frequent acute presentation followed by hypotension, bradycardia, reversible cardiomegaly and transient paroxysmal atrial fibrillation.<sup>34</sup> Case reports have described acute onset myocarditis in patients with SARS-CoV; however, on autopsy, the virus was absent in the myocardium, suggesting myocardial damage may be indirectly related to the illness.<sup>38,39</sup> Another report described several fatal cases of SARS-CoV patients with acute heart failure and, rarely, myocardial infarction in the setting of septic shock with elevated myocardial enzymes.<sup>40,41</sup> Chronic cardiometabolic damage may also ensue in some, even 12 years after recovery with dysregulated lipid metabolism.<sup>42</sup>

### MERS-CoV

There are rare case reports describing acute myocarditis in MERS-CoV patients, presenting with severe chest pain and subsequent heart failure with elevated high-sensitivity TnI and probrain natriuretic peptide levels<sup>22,43</sup> (Table 1). Few reports also note sinus tachycardia and diffuse T-wave inversion on electrocardiography and global left ventricular dysfunction on echocardiography.<sup>43</sup> Rarely pericarditis may also ensue.<sup>6</sup>

### COVID-19

ACE2, the functional receptor of COVID-19 is expressed in the myocardium. Whether the use of the renin-angiotensin-aldosterone system inhibitors alters COVID-19 infection by upregulating ACE2 is under

investigation. Similar to MERS-CoV and SARS-CoV, COVID-19 also causes acute cardiac injury in a subset of patients with corresponding elevated high-sensitivity cardiac troponin-I levels<sup>22,44</sup> (Table 1). CK-MB and high-sensitivity cardiac troponin-I were higher in ICU patients, suggesting that myocardial injury is more likely present in patients with severe disease.<sup>45,46</sup> As many as 7% of deaths in COVID-19 patients have been attributed to myocardial injury.<sup>47</sup> Other cardiac manifestations include acute myocardial infarction, fulminant heart failure and dysrhythmias.<sup>48</sup> In some studies, arrhythmia with COVID-19 infection was as high as 17%.<sup>20,45</sup> It is also important to note various drug interactions and the arrhythmogenic potential of medications often used in these patients. Additionally, patients with preexisting cardiovascular disease and hypertension have been seen to suffer from more severe disease requiring critical care.<sup>48</sup>

Presenting symptoms range from mild chest pain with preserved ejection fraction to profound cardiovascular collapse requiring extracorporeal membrane oxygenation. Echocardiography may show a regional wall motion abnormality or global hypokinesis with or without pericardial effusion.<sup>49,50</sup> Initial electrocardiogram may show low voltage QRS complexes in the limb leads, ST segment elevations in leads I, II, aVL, V2-V6 and PR elevation and ST depressions in aVR.<sup>49,50</sup> There should be a low threshold for SARS-CoV-2 testing in patients presenting with signs of myopericarditis even in the absence of fever and respiratory symptoms.

Proposed mechanisms of cardiac injury in patients with COVID-19 include overexpression of ACE2 in patients with chronic cardiovascular disease, cytokine storm triggered by an imbalanced response by type 1 and type 2 helper cells, hypoxemia resulting in myocardial damage, plaque rupture, coronary vasospasm, or direct vascular injury.<sup>22,45,51</sup> There may be a complex interplay between the accelerated immunologic dysregulation of the cytokines and T cells and the underlying cardiovascular or related metabolic conditions. Virally-induced systemic inflammation may also promote coronary plaque rupture and have a procoagulant effect necessitating the intensification of medical therapy.<sup>52</sup>

## HEPATOBIILIARY MANIFESTATIONS

### SARS-CoV

Hepatitis in SARS-CoV is a well-recognized common complication, although it is a diagnosis of exclusion. Approximately 60% of patients with SARS-CoV had a degree of liver impairment with elevated alanine aminotransferase and/or aspartate aminotransferase, hypoalbuminemia and hyperbilirubinemia<sup>53</sup> (Table 2). ACE2 receptors are also found on the hepatic endothelial cells.<sup>54</sup> On histopathology, SARS-CoV patients had a large number of virus particles in the hepatic parenchymal cells.<sup>38,39,55</sup> Elevated levels of IL-1, IL-6 and IL-10 in patients with SARS-CoV hepatitis support coexisting



**Table 2.** Cardiovascular manifestations of SARS-CoV, MERS-CoV and COVID-19.

<b>SARS (only studies with large study population included)</b>					
Study	Booth et al (2003) N = 144, confirmed cases Retrospective study	Li et al (2003) N = 46, confirmed cases Prospective study	Pan et al (2003) N = 15, confirmed cases Retrospective study	Ding et al (2004) N = 8 (4 confirmed cases, 4 control) Clinicopathologic study	Yu et al (2006) N = 121, confirmed cases Retrospective study
Clinical features	<ul style="list-style-type: none"> <li>• Chest pain (10%)</li> <li>• ↑HR (46%)</li> </ul>	<ul style="list-style-type: none"> <li>• No chest pain or overt CHF on admission</li> <li>• ↓HR (non-ICU) ↑HR (ICU)</li> <li>• CHF exacerbation</li> </ul>	<ul style="list-style-type: none"> <li>• Sudden cardiac arrest (100%)</li> <li>• MI and arrhythmia (33%)</li> </ul>	<ul style="list-style-type: none"> <li>• Chest pain</li> </ul>	<ul style="list-style-type: none"> <li>• ↑HR (71.9%) (62.8%, 45.4%, 35.5%)</li> <li>• ↓BP (50.4%) (28.1%, 21.5%, 14.8% during the first, second, third week) ↓HR, transient (14.9%)</li> <li>• Reversible cardiomegaly (10.7%), no clinical heart failure</li> <li>• Chest discomfort (7%)</li> <li>• Palpitations (4%)</li> </ul>
Key findings on investigations	<ul style="list-style-type: none"> <li>• ↓Ca<sup>++</sup> (60%)</li> <li>• ↓K<sup>+</sup> (26%)</li> <li>• ↓Mg<sup>++</sup> (18%)</li> <li>• ↓P<sup>+</sup> (27%)</li> <li>• ↑LDH (87%)</li> </ul>	<ul style="list-style-type: none"> <li>• ↑CK</li> <li>• ↑LDH</li> <li>• ↓Hb</li> <li>• EKG: RBBB</li> <li>• Echo: ↓LVEF</li> </ul>	<ul style="list-style-type: none"> <li>• Abnormal cardiac enzymes (66%)</li> </ul>	N/A	<ul style="list-style-type: none"> <li>• ↑CK</li> <li>• ↑CK (26%) without Tnl or CKMB</li> <li>• ↑LDH</li> <li>• CXR or CT abnormality: 100%</li> </ul>
Histopathology	N/A	N/A	N/A	<ul style="list-style-type: none"> <li>• Myocardial stromal edema</li> <li>• Infiltration of vessels by lymphocytes</li> <li>• Focal hyaline degeneration</li> <li>• Muscle fiber lysis</li> </ul>	N/A
Key study findings and message	<ul style="list-style-type: none"> <li>• 20% ICU admission</li> <li>• 6.5% Case fatality rate (21 days)</li> <li>• Diabetes and other comorbidities independently associated with poor prognosis</li> </ul>	Possibly reversible subclinical diastolic impairment seen in SARS patients	Proposed causes of SCD: <ul style="list-style-type: none"> <li>• Hypoxemia leading to myocardial strain</li> <li>• Direct viral myocardial injury</li> <li>• Stress aggravates pre-existing disease</li> <li>• Sympathetic response causing electrical myocardial instability</li> </ul>	ACE2 expressed in heart, but virus not detected	<ul style="list-style-type: none"> <li>• ↑CK likely due to myositis as cardiac enzymes normal</li> <li>• 15% ICU admission</li> <li>• 18 (5) days mean duration of hospital stay</li> <li>• Tachycardia persists during follow up</li> <li>• Cardiac arrhythmia is uncommon</li> </ul>
<b>MERS</b>					
Study	Alhoggani (2016) N = 1 confirmed case Case report		Almekhlafi et al (2016) N = 31, confirmed cases Retrospective study		Garout et al (2018) N = 52, confirmed cases Retrospective study
Clinical features	CHF		↑HR (67.7%)		Pericarditis
Key findings on investigations	<ul style="list-style-type: none"> <li>• ↑Tnl</li> <li>• ↑BNP</li> <li>• ↑Creatinine</li> </ul>		N/A		N/A

(continued on next page)

Table 2. (continued)

MERS					
	<ul style="list-style-type: none"> <li>Echo: Severe global LV dysfunction</li> <li>Cardiac MRI: Myocarditis</li> </ul>				
Key study findings and message	MERS-CoV may cause myocarditis and acute heart failure		<ul style="list-style-type: none"> <li>Vasopressor need is a risk factor for death (<math>P = 0.04</math>)</li> <li>80.6% vasopressor support rate</li> </ul>		No association of ECMO need with outcomes
COVID-19					
Study	Huang et al (2020) <i>N</i> = 41, confirmed cases Retrospective study	Wang et al (2020) <i>N</i> = 138, confirmed cases Retrospective study	Zheng et al (2020) Review	Bhatraju et al (2020) <i>N</i> = 24, confirmed cases Retrospective study	Fried et al (2020) <i>N</i> = 4, confirmed cases Case reports
Clinical features	<ul style="list-style-type: none"> <li>↑BP</li> <li>Acute cardiac injury (12%) more in ICU patients than non-ICU patients (31% vs. 4%)</li> </ul>	<ul style="list-style-type: none"> <li>Pre-existing HTN (31.2%) (58.3% in ICU, significant)</li> <li>Pre-existing CVD (14.5%) (25% in ICU, significant)</li> <li>Acute cardiac injury (7.2%) (22.2% in ICU, significant)</li> <li>Arrhythmia (16.7%) (44.4% in ICU patients)</li> </ul>	<ul style="list-style-type: none"> <li>Palpitations</li> <li>Chest tightness</li> </ul>	<ul style="list-style-type: none"> <li>↑HR (48%)</li> <li>Vasopressor need (71%)</li> </ul>	<ul style="list-style-type: none"> <li>Myopericarditis</li> <li>Decompensated heart failure</li> <li>Cardiogenic Shock</li> </ul>
Key findings on investigations	<ul style="list-style-type: none"> <li>↑ TnI (12%) (31% in ICU patients, 4% in non-ICU patients)</li> </ul>	<ul style="list-style-type: none"> <li>↑ TnI</li> <li>↑ CK-MB</li> </ul>	N/A	<ul style="list-style-type: none"> <li>↑ TnI (15%)</li> </ul>	<ul style="list-style-type: none"> <li>Diffuse ST segment elevations</li> <li>Elevated cardiac enzymes</li> <li>LVEF on echo</li> </ul>
Key Study findings and message	↑BP more common in ICU patients ( $P = 0.018$ )	ICU patients more likely to have pre-existing hypertension, develop arrhythmias, acute cardiac injury ( $P < 0.001$ )	Proposed mechanism of cardiac injury: <ul style="list-style-type: none"> <li>ACE 2 related</li> <li>Cytokine storm</li> <li>Hypoxemia</li> </ul>	ICU admission most commonly due to hypoxemic respiratory failure, vasopressor requirement or both	50% mortality
BNP, B-type natriuretic peptide; BP, blood pressure; HR, heart rate; CHF, congestive heart failure; CK, creatine kinase; CKMB, creatine kinase myocardial band; CXR; chest x-ray; ECMO, extracorporeal membrane oxygenation; Hb, hemoglobin; ICU, intensive care unit; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MERS-CoV, middle east respiratory syndrome coronavirus; RBBB, right bundle branch block; SARS-COV, severe acute respiratory syndrome coronavirus; TnI, troponin-I.					



acute inflammatory response.<sup>56</sup> Hepatic cell damage and cell-cycle disruption was seen on hepatic biopsy with apoptosis, mitotic arrest with eosinophilic bodies and balloon-like hepatocytes.<sup>22</sup> Unfortunately, hepatic damage potentially due to antivirals use complicates our understanding of the etiology of hepatitis in patients with SARS-CoV.<sup>57</sup> Hepatic involvement may indicate a poor prognosis, particularly in patients with high LDH levels.<sup>58</sup> Yang et al reported long-standing hyperglycemia (due to pancreatic injury) as an independent predictor for adverse outcomes in patients with SARS-CoV.<sup>58</sup>

### MERS-CoV

Several studies report patients with MERS-CoV and elevated liver enzymes, as well as hypoalbuminemia<sup>59,60</sup> (Table 2). The degree of hypoalbuminemia also helps to predict disease severity.<sup>60</sup> Hepatic findings may resemble SARS-CoV-related changes.<sup>61</sup> However, MERS-CoV utilizes dipeptidyl peptidase-4 to infect cells, which is highly expressed in the liver.<sup>62,63</sup> In transgenic mice, the liver injury occurred within the first week after infection resulting in hepatic necrosis and infiltration of Kupffer cells and macrophages.<sup>64</sup> Similar to other coronavirus infections, high concentrations of inflammatory cytokines are noted in the acute phase, including IFN- $\gamma$ , TNF- $\alpha$ , IL-15 and IL-17.<sup>65</sup> Future investigations may clarify the role of inflammatory response in causing the liver injury.

### COVID-19

The few available studies show that as many as 51% of patients with COVID-19 have abnormal liver function on admission (elevated liver enzymes, bilirubin and lactate dehydrogenase levels)<sup>66</sup> (Table 2). Patients with abnormal LFTs present with a high degree of fever, and their degree of hepatic dysfunction correlates with length of hospitalization.<sup>66</sup> New reports suggest that the liver dysfunction in patients with COVID-19 may be related to damage to the cholangiocytes lining the biliary epithelium, likely due to the higher expression of ACE2 receptors on those cells.<sup>67</sup> Patients with preexisting metabolic fatty liver disease have been seen to have an about 6-fold higher chance of severe disease in the presence of coexisting obesity.<sup>21</sup>

## GASTROINTESTINAL MANIFESTATIONS

### SARS-CoV

Gastrointestinal (GI) involvement in SARS-CoV was common and occurred at different stages of the disease; rarely, patients reported only GI symptoms.<sup>68-70</sup> The most common GI presentation was loss of appetite (up to 55%) and watery diarrhea (up to 76%)<sup>69,71</sup> (Table 3). Patients also complained of nausea, vomiting (14-22.2%) and abdominal pain (3.5-12.6%).<sup>72</sup> The association between symptoms and outcomes had been mixed. Leung et al found that patients with diarrhea had a higher

likelihood of requiring ICU admission and ventilatory support.<sup>68</sup> Others found that GI symptoms at presentation conferred a better prognosis.<sup>69</sup> Others found no association between diarrhea and the development of ARDS or the requirement of ventilatory support.<sup>70</sup> The mechanism of GI symptoms is unclear, but SARS-CoV particles have been detected in saliva (100%), feces (97%) and mucosal epithelial and lymphoid tissue of affected patients with associated depletion of lymphoid tissue.<sup>72</sup>

A significant mode of spread in community outbreaks was fecal-oral transmission.<sup>70,73,74</sup> Patients with diarrhea also had a higher rate of positive serological and nasopharyngeal secretion tests.<sup>75</sup> The virus remained stable in stool up to 2-4 days, and may even be detectable as late as 4 weeks.<sup>70,73,76</sup>

### MERS-CoV

Patients may present with GI symptoms, pain and fever<sup>16,77,78</sup> (Table 3). Patients with GI symptoms have delayed MERS-CoV serological clearance.<sup>60,79</sup> MERS-CoV RNA in stool has been detected in about 15% of patients, much lower than SARS-CoV, and may not correlate with the presence of GI symptoms.<sup>79,80</sup> While the virus replicates in the intestinal tract, isolation of the virus from feces and fecal-oral transmission are rare.<sup>81-83</sup>

### COVID-19

There is increasing recognition of GI symptoms in COVID-19 patients (up to 50%).<sup>84</sup> Patients may present only with GI symptoms.<sup>20,84</sup> Loss of appetite and diarrhea have been the most commonly reported symptom (in up to 78.6% cases), and less often vomiting (up to 5%), and abdominal pain (up to 2%) (Table 3).<sup>20-22,84</sup> Vomiting has been shown to be a more common presenting symptoms in children. The GI features seem to worsen with overall disease severity and the presence of abdominal pain has been associated with about 4 times higher odds of severe COVID.<sup>22,24</sup> The delayed recognition of GI symptoms and lack of awareness may lead to a delay in seeking medical care.<sup>22</sup> Patients who present later during their illness were more likely to suffer from hepatic dysfunction but without a difference in mortality, ICU days or time to discharge.<sup>22</sup> Patients with obesity are at significantly higher risk for severe disease requiring critical care and invasive mechanical ventilation. Compared with patients with a BMI <25 kg/m<sup>2</sup>, patients with BMI >35 kg/m<sup>2</sup> have been seen to have 7 times the odds for requiring invasive mechanical ventilation.<sup>25,26</sup>

COVID-19 virus enters enteric epithelial tissue through ACE 2 and transmembrane protease, serine 2, but the exact mechanism of GI symptoms is not known.<sup>85</sup> The virus is detectable in stool in up to half of COVID-19 patients,<sup>86,87</sup> and the feces remains positive for as much as 4 weeks.<sup>87</sup> ACE 2 and viral protein have been detected in GI epithelial cells, and infectious virus particles were isolated from feces.<sup>88</sup> Fecal polymerase chain reaction (PCR) testing has been shown to be as

**Table 3.** Hepatobiliary manifestation of SARS-CoV, MERS-CoV and COVID-19.

SARS (only studies with large study population included)							
Study	Duan et al (2003) N = 154, confirmed cases Retrospective study	Ding et al (2004) N = 8 (4 confirmed cases, 4 control) Clinicopathologic study	Chau et al (2004) N = 3, confirmed Case report	Zhao et al (2004) N = 169, confirmed cases Retrospective study	Yang et al (2005) N = 168, confirmed cases Retrospective study	Zhan et al (2006) N = 12 (6 confirmed cases, 6 controls) Clinicopathologic study	Yang et al (2010) N = 539 (520 confirmed cases) Prospective study
Clinical Features	Hepatic dysfunction	Hepatic dysfunction	Hepatic dysfunction	Hepatic dysfunction	Hepatic dysfunction		Diabetes: • 35.9% within 3 days • 51.3% within 2 weeks ↑ blood glucose
Key findings on investigations	<ul style="list-style-type: none"> <li>• ↑ALT &amp;/or AST (37.7%)</li> <li>• ↑ALT (70.7%)</li> <li>• ↑ALT and AST (22.4%)</li> <li>• ALT and AST normalized within 2 weeks in 75.9%</li> <li>• ↑T. bili (8.4%)</li> <li>• ↑Albumin (24%)</li> <li>• ↓ Prealbumin (28.6%)</li> </ul>		<ul style="list-style-type: none"> <li>• ↑ ALT</li> <li>• + viral RT-PCR in liver, not sera</li> </ul>	<ul style="list-style-type: none"> <li>• ↑ ALT (32.76-62.50%)</li> <li>• ↑ AST (13.04-40.00%)</li> <li>• ↓ Albumin (40.35-72.00%)</li> <li>• Total protein remained normal</li> </ul>	<ul style="list-style-type: none"> <li>• ↑ ALT:</li> <li>• Peak: 111.32 ± 160.24 U/L</li> <li>• At admission: 52.5%</li> <li>• First week: 71.8%</li> <li>• Second week: 85.7%</li> <li>• Third week: 85.2%</li> <li>• ↓ Albumin</li> </ul>		
Histopathology	N/A	<ul style="list-style-type: none"> <li>• Virus detected in liver, pancreas</li> <li>• Virus not detected in spleen.</li> </ul>	<ul style="list-style-type: none"> <li>• Apoptosis (3/3)</li> <li>• Accumulated cells in mitosis (2/3)</li> <li>• Ballooning hepatocytes</li> <li>• Mild to moderate lobular lymphocytic infiltration</li> <li>• Ki-67 + nuclei (0.5-11.4%)</li> <li>• Virus detected in liver by RT-PCR, but not by EM</li> </ul>	N/A	Nonspecific inflammation	Spleen: <ul style="list-style-type: none"> <li>• Severe white pulp damage</li> <li>• Altered cell distribution</li> <li>• Markedly reduced or absent CD3+, CD4+, and CD8+ cells</li> <li>• CD68+ macrophages most numerous</li> </ul>	ACE2 receptors found in pancreatic islet cells
Key study findings and message	<ul style="list-style-type: none"> <li>• AST/ALT elevation rates associated with disease severity (<math>P &lt; 0.05</math>)</li> <li>• Possibly beneficial to suppress cytokine storm in early stage</li> </ul>	Liver may also be target of infection besides lungs	Liver damage likely by virus directly	Total protein remained normal despite albuminemia	<ul style="list-style-type: none"> <li>• No association found between liver damage, and oxygen saturation or degree of fever or immune dysfunction</li> <li>• Liver damage likely by virus directly</li> <li>• Hepatotoxic drugs may contribute</li> </ul>	<ul style="list-style-type: none"> <li>• Spleen damage most likely due to direct viral attack</li> <li>• Steroid medication may contribute</li> <li>• Indirect viral mechanism, perhaps vascular, causing spleen injury</li> </ul>	<ul style="list-style-type: none"> <li>• Higher mortality in patients with hyperglycemia, ↑ AST (<math>P &lt; 0.0001</math>)</li> <li>• Mortality not higher in patients with ↑ ALT (<math>P = 0.35</math>)</li> <li>• SARS-CoV may cause acute insulin dependent diabetes mellitus</li> <li>• 5% (2/39) still had diabetes 3 years after discharge</li> </ul>
MERS							
Study	Saad et al (2014) N = 70, confirmed cases Retrospective		Al-Hameed et al (2016) N = 8, confirmed cases Prospective study		Alsaad et al (2017) N = 1, confirmed cases Clinicopathologic		
Clinical Features	Hepatic dysfunction (31.4%)		Hepatic dysfunction later during ICU stay (62.5%)		N/A		
Key findings on investigations	<ul style="list-style-type: none"> <li>• ↓ Albumin</li> <li>• ↑ AST</li> <li>• ↑ T.bil</li> </ul>		<ul style="list-style-type: none"> <li>• ↑ AST, ALT</li> <li>• ↑ T.bil</li> </ul>		N/A		
Histopathology	N/A		N/A		Liver:		

(continued on next page)

**Table 3. (continued)**

MERS				
				<ul style="list-style-type: none"> <li>• Mild portal inflammation, chronic, with CD4+ and CD8+ T lymphocytes. Necroinflammatory foci in hepatic lobules</li> <li>• Reactive parenchyma with mild hydropic degeneration, more in perivenular area</li> <li>• Rare multinucleated hepatocytes</li> <li>• Mild disarray of the hepatic plates</li> <li>• Minimal macrovesicular perivenular steatotic change, sinusoidal congestion, hemorrhage and focal perivenular hepatocytes loss</li> </ul>
Key study findings and message	Albumin <35 g/L at diagnosis predictor of severe infection ( $P = 0.026$ )	41% developed multiorgan failure		Portal and lobular hepatitis, viral particles not identified in liver on EM
COVID-19				
Study	Fan et al (2020) $N = 148$ , confirmed cases Retrospective study	Chai et al (2020) $N = 4$ (healthy) Clinicopathologic	Huang et al (2020) $N = 41$ , confirmed cases Retrospective study	Wang et al (2020) $N = 138$ , confirmed cases Retrospective study
Clinical features	Hepatic dysfunction at admission (50.7%)		Preexisting chronic liver disease (2%)	Pre-existing chronic liver disease (2.9%)
Key findings on investigations	↓ CD4+ and CD8+ T cells in patients with hepatic dysfunction	N/A	↑ AST (37%)(62% ICU, 25% non-ICU)	↑ LDH
Histopathology	N/A	ACE2 expression in cholangiocytes (59.7%) and hepatocytes (2.6%)	N/A	N/A
Key study findings and message	<ul style="list-style-type: none"> <li>• Patients with hepatic dysfunction more likely to have moderate-high fever, more in males (<math>P = 0.035, 0.005</math>)</li> <li>• Abnormal liver function after admission associated with prolonged stay (<math>P = 0.02</math>)</li> </ul>	<ul style="list-style-type: none"> <li>• Hepatic dysfunction more likely due to cholangiocyte damage by virus, not hepatocyte</li> <li>• Drug induced damage, SIRS may also play a role</li> </ul>	Cytokine storm possible associated with disease severity	AST, ALT, T.bil, LDH higher in ICU patients ( $P < 0.001, P = 0.007, P = 0.02, P < 0.001$ )
<p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; MERS-CoV, middle east respiratory syndrome coronavirus; RT-PCR, reverse transcriptase polymerase chain reaction; SARS-COV, severe acute respiratory syndrome coronavirus; T. Bili, total bilirubin.</p>				

accurate as PCR detection from a sputum sample, and in some cases, fecal PCR is positive before sputum PCR.<sup>88</sup> It remains unclear if the fecal-oral route is a significant mode of transmission.

## RENAL MANIFESTATIONS

### SARS-CoV

Renal impairment in SARS-CoV seems multifactorial and could include secondary sepsis, comorbidities, rhabdomyolysis, treatment-related interstitial nephritis, and altered immune response (Table 4). In most SARS-CoV patients, acute renal damage was not common at presentation.<sup>89</sup> However, acute renal failure was noted in 5-15% of patients and more often developed subsequently 7-20 days after presentation.<sup>89-92</sup> Choi et al reported a 6% incidence of acute renal failure in a study of 267 patients, more commonly in elderly diabetics. A large study with 536 patients stated that patients with ARF had hyponatremia and hypoalbuminemia at the time of admission.<sup>75,91</sup> Patients with renal dysfunction had mortality rates around 90%.<sup>75,90,91,93,94</sup> Patients with hypouricemia and chronic renal replacement therapy also had poor outcomes.<sup>95-97</sup>

On microscopy, acute tubular necrosis has been observed in these patients.<sup>91</sup> Viral detection in the urine at the onset was rare but gradually increased with the disease progression and remained detectable up to 30 days after symptom onset.<sup>76,98</sup> Xu et al reported that 6 patients who died of SARS-CoV had testicular damage, which was also likely secondary to the immune response.<sup>99</sup>

### MERS-CoV

MERS-CoV uses the exopeptidase dipeptidyl peptidase 4 or CD 26 as its cellular receptor, which is highly expressed in kidneys.<sup>100</sup> Renal involvement is as high as 41% and required dialysis more than SARS-CoV patients<sup>4,17,60</sup> (Table 4). Cha et al reported ( $n = 30$  patients), 60% and 73% of patients with proteinuria and hematuria, respectively, approximately 27% of them developed acute kidney injury within 18 days. Patients with acute kidney injury were older and had elevated levels of albumin to creatinine ratios. Patients requiring renal replacement therapy had a higher mortality. Preexisting chronic kidney disease is also a predictor of poor outcomes.<sup>16,101,102</sup> The virus has been detected in urine and renal tissue and causes apoptosis, suggesting direct viral pathogenicity complements the other mechanisms of renal injury.<sup>17,61,103</sup>

### COVID-19

Acute renal dysfunction in COVID-19 at the time of presentation is not uncommon.<sup>92,104,105</sup> The incidence of acute kidney injury either at presentation or later is as high as 15% with a high mortality rate of 60-90%<sup>106,107</sup> (Table 4). Other researchers report albuminuria or

proteinuria on admission in 44-63% patients, hematuria in 27%, elevated urea and creatinine in 13-27% and 14-19%, respectively, and low eGFR in 13%.<sup>104,105</sup> There may also be imaging evidence of active renal edema and inflammation.<sup>104</sup> Since renal dysfunction is early, an immunopathology response or direct viral injury may be contributing along with other systemic factors.<sup>20,92</sup> Similar to other novel CoVs, renal involvement, acute or chronic, tends to associate with an adverse prognosis.<sup>22,105,107</sup> The COVID-19 virus has been detected in renal tissue and in the urine.<sup>39,70,108</sup> Due to the presence of ACE2 receptors in the Leydig cells and seminiferous tubules, it is also reasonable to speculate that testicular injury may be a consequence of COVID-19 infection.<sup>109</sup>

## NEUROLOGIC MANIFESTATIONS

### SARS-CoV

Patients with SARS-CoV presented with ischemic stroke, likely due to the hypercoagulable state and vasculitis induced during the illness<sup>110</sup> (Table 5). Case reports mentioned the detection of SARS-CoV in the cerebral spinal fluid (CSF) of patients who subsequently developed seizures.<sup>111,112</sup> Tsai et al studied 4 patients with SARS-CoV who developed neuropathy and myopathy. Since they did not find CSF evidence of viral invasion, they attributed these findings to critical illness polyneuropathy and myopathy.<sup>113</sup>

Ocular manifestations have not been widely reported in patients with SARS-CoV infection. However, in 1 case report, tears from a female patient were analyzed by PCR and shown to be positive for SARS-CoV when other testing methods were negative. Still, risk of SARS-CoV transmission through tears remains low.

### MERS-CoV

MERS-CoV causes both central and peripheral neurological abnormalities. Neurological symptoms occur later in the course of the illness as weakness and neuropathy and less frequently hypersomnolence and ataxia (Table 5).<sup>114,115</sup> In a study of 4 patients with neurological symptoms conducted by Kim et al, MERS-CoV was not detected in the CSF, however, patients developed Guillain-Barre' syndrome, Bickerstaff's encephalitis, critical illness myopathy, viral myopathy or toxin associated myopathy and neuropathy.<sup>114</sup> Algahtani et al also report a case of cerebrovascular accident attributable to disseminated intravascular coagulation (DIC) and viral-induced autoimmune response.<sup>115</sup> The authors are not aware of evidence describing the ocular manifestations of MERS-CoV or the ability to isolate the virus in tear samples.

### COVID-19

Increasingly recognized sensory symptoms of COVID-19 infection include the sudden onset of anosmia, and, to a lesser extent, dysgeusia (Table 6).<sup>40</sup>

**Table 4.** Gastrointestinal manifestations of SARS-CoV, MERS-CoV and COVID-19.

<b>SARS (only studies with large study population included)</b>							
Study	Lee et al (2003) N = 138, suspected Retrospective study	Donnelly et al (2003) N = 1425, confirmed cases Retrospective study	Peiris et al (2003) N = 75, confirmed cases Prospective study	Leung et al (2003) N = 138, confirmed cases Retrospective study	Choi et al (2003) N = 267 (227 confirmed cases) Retrospective study	Shi et al (2005) N = 14, (7 confirmed cases, 7 suspected) Clinicopathologic study	Kwan et al (2005) N = 240, confirmed cases Retrospective Study
Clinical Features	<ul style="list-style-type: none"> <li>• Diarrhea (19.6%)</li> <li>• Nausea and vomiting (19.6%)</li> </ul>	<ul style="list-style-type: none"> <li>• Loss of appetite (54.6%)</li> <li>• Diarrhea (27%)</li> <li>• Vomiting (14%)</li> <li>• Abdominal pain (13%)</li> </ul>	Watery diarrhea (73%) (1% on admission) <ul style="list-style-type: none"> <li>• 7.5 ± 2.3 days of symptom onset</li> <li>• frequency 6.3 ± 3.5/day</li> <li>• Peak 8.7 ± 2.3 days, improved in all by day 13</li> </ul>	Watery diarrhea (38.4 % within first week, 20.3% on presentation) <ul style="list-style-type: none"> <li>• Average duration: 3.7 ± 2.7</li> <li>• 5.8% only GI symptoms on presentation</li> </ul>	<ul style="list-style-type: none"> <li>• Loss of appetite (23%)</li> <li>• Watery diarrhea (15% on admission, increased to 53% after hospitalization, median 3 days after) (frequency 3-20/day)</li> <li>• Vomiting (7%)</li> </ul>	<ul style="list-style-type: none"> <li>• Diarrhea (1/7)</li> <li>• Upper GI hemorrhage (2/7)</li> <li>• Hematochezia (1/7)</li> </ul>	<ul style="list-style-type: none"> <li>• Watery diarrhea (20.4%)</li> <li>• 7.5 ± 2.8 days after fever onset</li> <li>• (Peak day 12)</li> <li>• OR: 3 for patients with diarrhea to have continued diarrhea on follow up</li> </ul>
Key findings on investigations	<ul style="list-style-type: none"> <li>• ↑ baseline albumin</li> <li>• ↓ K<sup>+</sup></li> </ul>	N/A	Viral RNA in stool (97%) (14.4 ± 2.2 days from onset)	<ul style="list-style-type: none"> <li>• ↓ K<sup>+</sup></li> <li>• Viral RNA in stool (16%)</li> <li>• No viral isolation from stool</li> <li>• Colonoscopy (1) grossly within normal limits</li> </ul>	↓ K <sup>+</sup> (41%)	N/A	K <sup>+</sup> nadir lower in diarrheal patients than nondiarrheal (P < 0.05)
Histopathology	N/A	N/A	N/A	<ul style="list-style-type: none"> <li>• On EM, viral particles detected in epithelial cells of bowel within ER, and in surface microvilli, active viral replication in intestines</li> <li>• Able to isolate virus by culture from small intestine</li> </ul>	N/A	<ul style="list-style-type: none"> <li>• Diarrheal patient: Pseudomembranous plaques, shallow ulcers in TI, scattered hemorrhagic spots in gastric mucosa</li> <li>• Patients with bleeding: coffee ground liquid in GIT</li> <li>• Lymphoid tissue depletion in all</li> <li>• SARS-CoV particles detected in epithelial cells in diarrheal patient only</li> </ul>	N/A
Key study findings and GI symptoms were less message	GI symptoms were less common	GI symptoms less common at presentation	21%: concomitant fever, diarrhea, and radiological worsening	<ul style="list-style-type: none"> <li>• Patients with GI symptoms had higher ICU admission (P &lt; 0.001, higher requirement of ventilatory support (P = 0.004)</li> <li>• GI symptoms may be due to proteins or toxins produced during viral replication</li> </ul>	<ul style="list-style-type: none"> <li>• Diarrheal patients had nonstatistically significant higher rates of positive serological and nasopharyngeal secretion testing</li> <li>• GI symptoms may be due to direct enteric infection by virus or antibiotic treatment</li> </ul>	GI symptoms may be due to: <ul style="list-style-type: none"> <li>• Acute immune damage</li> <li>• Via infected lymphocytes</li> <li>• Opportunistic infections</li> </ul>	GI symptoms more common in: <ul style="list-style-type: none"> <li>• F&gt;M (6:1) (P &lt; 0.001)</li> <li>• Geographical (Amoy Gardens Estate residents) (P = 0.01)</li> <li>• Patients with GI symptoms had lower mortality and ventilator requirement (P &lt; 0.005)</li> </ul>

(continued on next page)

Table 4. (continued)

SARS (only studies with large study population included)						
						<ul style="list-style-type: none"> <li>CXR scores at peak of diarrhea did not correlate with frequency</li> </ul>
MERS						
Study	Assiri et al (2013) N = 47, confirmed cases Retrospective study	Corman et al (2015) N = 37, confirmed cases Clinicopathologic study	Alenazi et al (2017) N = 130, confirmed cases Clinicopathologic study	Zhou et al (2017) Human intestinal epithelial cell culture, hDDP4 transgenic mice Clinicopathologic	Al-Abdley et al (2019) N = 33, confirmed cases Clinicopathologic study	
Clinical features	<ul style="list-style-type: none"> <li>Diarrhea (26%)</li> <li>Nausea (21%)</li> <li>Vomiting (21%)</li> <li>Abdominal pain (17%) (at presentation)</li> </ul>	N/A	GI symptoms in <ul style="list-style-type: none"> <li>Community acquired infection: 46.2%</li> <li>Healthcare associated infection: 46.6%</li> <li>HAI in healthcare workers: 16%</li> </ul>	N/A	<ul style="list-style-type: none"> <li>Vomiting (31%)</li> <li>Diarrhea (15%)</li> </ul>	
Key findings on investigations	N/A	<ul style="list-style-type: none"> <li>14.6% stool yielded viral RNA</li> </ul>	N/A	N/A	RNA positive stool (57%) did not correlate with presence of GI symptoms	
Key study findings and message	GI symptoms are frequent at presentation	<ul style="list-style-type: none"> <li>Viral load in stool is significantly lower than in lower respiratory tract</li> <li>Virus not cultivable from stool</li> </ul>	MERS-CoV high in healthcare environment	<ul style="list-style-type: none"> <li>GI symptoms among the commonest extrapulmonary symptoms</li> <li>Intestinal epithelial cells could support viral replication</li> <li>Primary gastric infection can lead to respiratory symptoms via hematogenous or lymphatic spread</li> </ul>	Diarrhea may be associated with prolonged viral detection (p 0.069)	
COVID-19						
Study	Wang et al (2020) N = 138, confirmed cases Clinicopathologic study	Guan et al (2020) N = 1099, confirmed cases Retrospective study	To et al (2020) N = 12, suspected cases Clinicopathologic study	Xie et al (2020) N = 19 suspected (9 confirmed cases) Clinicopathologic study	Pan et al (2020) N = 204, confirmed cases Retrospective study	Wu et al (2020) N = 74, confirmed cases Clinicopathologic study

(continued on next page)

**Table 4. (continued)**

COVID-19						
Clinical features	<ul style="list-style-type: none"> <li>Anorexia (39.9)</li> <li>Diarrhea (10.1)</li> <li>Nausea (10.1%)</li> <li>Vomiting (3.6%)</li> <li>Abdominal pain (2.2%)</li> </ul>	<ul style="list-style-type: none"> <li>Diarrhea (3.8%)</li> <li>Nausea or vomiting (5%)</li> </ul>		Diarrhea (11.1% of confirmed)	<ul style="list-style-type: none"> <li>Any GI symptom: 50.5%</li> <li>Only GI symptoms: 0.03%</li> <li>Loss of appetite (39.7% of total, 78.6% of all GI symptoms)</li> <li>Diarrhea (17.1%, 34%, usually 3/day)</li> <li>Vomiting (0.02%, 3.9%)</li> <li>Abdominal pain (0.01%, 1.9%)</li> </ul>	Diarrhea/Vomit/Stomachache (44.6%)
Key findings on investigations	N/A	N/A	<ul style="list-style-type: none"> <li>2019-nCoV detected in 91.7% saliva samples</li> <li>Virus cultured from 3/12 saliva samples</li> </ul>	RNA positive stool samples: 88.9% of confirmed (overall 42%)	↑ALT, AST ↑ PT ↓monocyte count	<ul style="list-style-type: none"> <li>RNA positive stool samples: 55%</li> </ul>
Key study findings and message	ICU patients more likely to have anorexia and abdominal pain ( $P < 0.001$ , $P = 0.02$ )	GI symptoms less common		<ul style="list-style-type: none"> <li>Presence of GI symptoms not associated with stool RNA positivity</li> <li>Fecal transmission possible</li> </ul>	<ul style="list-style-type: none"> <li>Patients with GI symptoms had longer interval from symptom onset to admission (<math>P = 0.013</math>)</li> <li>GI symptoms worsened with severity of disease</li> <li>Patients with GI symptoms more likely to get antibiotics (<math>P = 0.018</math>)</li> <li>No association presence of GI symptoms with total hospital stay, ICU days or mortality</li> </ul>	<ul style="list-style-type: none"> <li>Presence of GI symptoms not associated with stool positivity</li> <li>Prolonged fecal viral shedding up to 5 weeks</li> <li>Disease severity not associated with prolonged fecal viral shedding</li> <li>Fecal transmission possible</li> </ul>
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CXR, chest x-ray; EM, electron microscopy; F, female; GIT, gastrointestinal tract; HAI, healthcare associated infection; HAI, healthcare associated infection; MERS-CoV, middle east respiratory syndrome coronavirus; SARS-COV, severe acute respiratory syndrome coronavirus; TI, terminal ileumx.						



**Table 5.** Renal manifestations of SARS-CoV, MERS-CoV and COVID-19.

<b>SARS (only studies with large study population included)</b>							
Study	Booth et al (2003) N = 144, confirmed cases Retrospective study	Choi et al (2003) N = 267 (227 confirmed cases) Retrospective study	Zou et al (2004) N = 165, confirmed cases Retrospective study	Chan et al (2004) N = 669, (323 tested positive) Clinicopathologic study	Huang et al (2004) N = 78, probable Retrospective study	Ding et al (2004) N = 8 (4 confirmed cases, 4 control) Clinicopathologic study	Chu et al (2005) N = 536, confirmed cases Retrospective study
Clinical features	Renal dysfunction	ARF (6%) during course of hospitalization	Renal dysfunction	N/A	ARF (17%), 7.2 ± 4.3 days after admission	N/A	ARF (6.7%) within 5-48 days of onset (median 20)
Key findings on investigations	<ul style="list-style-type: none"> <li>• ↑ Cr</li> <li>• ↑ Urea</li> <li>• ↓Ca++ (60%)</li> <li>• ↓K+ (26%)</li> <li>• ↓Mg++ (18%)</li> <li>• ↓P+ (27%)</li> <li>• ↑ LDH (87%)</li> </ul>	↑ Cr	↑ Cr ↑ Urea	<ul style="list-style-type: none"> <li>• Virus first detected in urine on day 7, started to decline after day 16</li> </ul>	↑ Cr	N/A	Cr normal at presentation, then ↑
Histopathology	N/A	N/A	N/A	N/A	N/A	Virus detected in distal convoluted renal tubule	Acute tubular necrosis, no evidence of glomerular pathology
Key study findings and message	↑ Urea > ↑ Cr associated with mortality ( $P = 0.003$ , $P = 0.02$ )	↑ Cr associated with mortality ( $P < 0.001$ , univariate)	↑ Cr, ↑ Urea associated with poor prognosis ( $P = 0.001$ , $P = 0.003$ )	Virus can persist >30 days after symptom onset in urine	<ul style="list-style-type: none"> <li>• ARF more common in older age, males (<math>P &lt; 0.05</math>), diabetics (<math>P &lt; 0.01</math>), patients with heart failure (<math>P &lt; 0.001</math>)</li> <li>• Renal features may be due to pre-renal factors, hypotension, rhabdomyolysis, comorbidities including diabetes, age</li> </ul>	ACE2 expressed and virus detected in kidneys	<ul style="list-style-type: none"> <li>• ARF significant risk factor for mortality (<math>P &lt; 0.001</math>) (uni and multivariate)</li> <li>• ARF more likely in older age group, patients with ARDS, and requiring inotropes (<math>P &lt; 0.001</math>)</li> <li>• ↓albumin, ↑ ALT at presentation, ↑ peak CPK after admission associated with development of ARF (<math>P &lt; 0.001</math>, <math>P = 0.004</math>, <math>P &lt; 0.001</math>)</li> <li>• Renal features likely multiorgan failure related, no direct viral pathology</li> </ul>
<b>MERS</b>							
Study	Assiri et al (2013) N = 47, confirmed cases Retrospective study	Arabi et al (2014) N = 12 (11 confirmed cases, 1 probable) Case series	Saad et al (2014) N = 70, confirmed cases Retrospective study	Cha et al (2015) N = 30, confirmed cases Retrospective study	Yeung et al (2016) Ex-vivo organ culture Nonhuman primate model Clinicopathologic	Alsaad et al (2017) N = 1, confirmed cases Clinicopathologic study	
Clinical feature	Coexisting chronic renal disease (49%)	<ul style="list-style-type: none"> <li>• Coexisting chronic renal disease (42%)</li> <li>• ARF requiring RRT (58%)</li> </ul>	ARF (42.9%)	<ul style="list-style-type: none"> <li>• Coexisting chronic renal disease (10%)</li> <li>• ARF (26.7%)</li> </ul>	N/A		
Histopathology	N/A	N/A	N/A	N/A	Smad7 and FGF2 expression elevated in kidneys of infected animals	<ul style="list-style-type: none"> <li>• Tubular epithelial cell degenerative and regenerative changes</li> <li>• Mild glomerular ischemic changes</li> </ul>	

(continued on next page)

**Table 5. (continued)**

MERS					
Key study findings and message	Chronic renal disease was a common comorbidity	Renal features may be due to: <ul style="list-style-type: none"> <li>• Cytokine dysregulation</li> <li>• Direct viral invasion</li> <li>• Autoimmune</li> </ul>	Acute kidney injury is a common complication	<ul style="list-style-type: none"> <li>• AKI more likely in older patients (<math>P = 0.016</math>)</li> <li>• Preexisting CKD not associated with later development of AKI</li> <li>• AKI, RRT risk factors for mortality (univariate)</li> </ul>	MERS-CoV induced apoptosis via upregulation of Smad7 and FGF2 expression  • Viral particles detected in proximal tubular epithelial cells Tissue trophism in kidneys
COVID-19					
Study	Wang et al (2020) <i>N</i> = 138, confirmed cases Retrospective study	Cheng et al (2020) <i>N</i> = 701, confirmed cases Retrospective study	Wang et al (2020) <i>N</i> = 205, confirmed cases Clinicopathologic	Li et al (2020) <i>N</i> = 193, confirmed cases Retrospective study	Zhou et al (2020) <i>N</i> = 191, confirmed cases Retrospective study
Clinical Features	<ul style="list-style-type: none"> <li>• Coexisting chronic renal disease (2.9%)</li> <li>• AKI (3.6%)</li> </ul>	<ul style="list-style-type: none"> <li>• Coexisting chronic renal disease (2%)</li> <li>• AKI (3.2%)</li> </ul>	N/A	<ul style="list-style-type: none"> <li>• AKI (28%)</li> </ul>	<ul style="list-style-type: none"> <li>• AKI (15%) (Av 15 days after symptom onset)</li> </ul>
Key findings on investigations	↑ Cr	<ul style="list-style-type: none"> <li>• ↑ Cr (14.4%)</li> <li>• ↑ Urea (13.1%)</li> <li>• eGFR &lt; 60 (13.1%)</li> <li>• Proteinuria (43.9%)</li> <li>• Hematuria (26.7%)</li> </ul>	No viral detection in urine (72 samples)	<ul style="list-style-type: none"> <li>• ↑ Cr (10%)</li> <li>• ↑ Urea (14.%)</li> <li>• Proteinuria (59%)</li> <li>• Hematuria (44%)</li> </ul>	↑ Cr
Key study findings and message	<ul style="list-style-type: none"> <li>• ICU patients more likely to have ↑ Cr (<math>P = 0.04</math>), ↑ BUN (0.001)</li> <li>• Cr and urea increased with disease progression</li> </ul>	<ul style="list-style-type: none"> <li>• ↑ Cr at admission more common in males, older patients, more severe disease (<math>P &lt; 0.001</math>, <math>P &lt; 0.001</math>, <math>P = 0.026</math>)</li> <li>• AKI, in hospital death, mechanical ventilation more common in patients with baseline ↑ Cr (<math>P &lt; 0.001</math>, <math>P &lt; 0.001</math>, <math>P = 0.012</math>)</li> <li>• Higher in hospital death rate with proteinuria, hematuria, baseline ↑ Cr, Urea, AKI Stage 2 or 3 (<math>P &lt; 0.001</math>; <math>P = 0.003</math> for AKI stage 1)</li> <li>• Renal features may be due to direct viral effect, immune mediated, virus induced cytokines and mediators.</li> </ul>	No viral shedding in urine	AKI associated with severe outcome ( $P < 0.001$ )	<ul style="list-style-type: none"> <li>• ↑ Cr associated with in-hospital death (<math>P = 0.045</math>)</li> <li>• Higher incidence of AKI in nonsurvivors (<math>P &lt; 0.001</math>)</li> </ul>
ACE2, Angiotensin-converting enzyme 2; AKI, acute kidney injury; ARF, acute renal failure; BUN, blood urea nitrogen; CKD, chronic kidney disease; CPK, creatine phosphokinase; Cr, creatinine; eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase; MERS-CoV, middle east respiratory syndrome coronavirus; SARS-COV, severe acute respiratory syndrome coronavirus; RRT, rapid response team.					

**Table 6.** Neurological manifestations of SARS-CoV, MERS-CoV and COVID-19.

<b>SARS (only studies with large study population included)</b>					
Study	Hung et al (2003) N = 1, confirmed cases Case report	Lau et al (2004) N = 1, confirmed cases Case report	Tsai et al (2004) N = 4, confirmed cases Case reports	Tsai et al (2005) N = 664, probable Retrospective study	
Clinical features	Seizures (4 limb twitching) starting day 5, lasting up to 30 min	Seizures (GTCS) started on day 22	<ul style="list-style-type: none"> <li>Neurological disturbances - 3 weeks after symptom onset</li> <li>Motor predominant peripheral neuropathy (50%)</li> <li>Myopathy (25%)</li> <li>Myopathy and Neuropathy (25%)</li> <li>Mild hyporeflexia (75%)</li> <li>Hypesthesia in legs (75%)</li> </ul>	<ul style="list-style-type: none"> <li>Axonopathic polyneuropathy (2) 3-4 weeks after onset</li> <li>Myopathy (2)</li> <li>Rhabdomyolysis (3)</li> <li>Large vessel ischemic stroke (5)</li> </ul>	
Key findings on investigations	CSF: <ul style="list-style-type: none"> <li>↑ glucose</li> <li>SARS-CoV RNA detected</li> </ul>	CSF: <ul style="list-style-type: none"> <li>SARS-CoV RNA detected</li> <li>Normal cell counts, glucose, opening pressure</li> </ul>	<ul style="list-style-type: none"> <li>Virus not detected in CSF</li> <li>↑ CK</li> <li>↑ Myoglobin</li> <li>Nerve conduction studies: ↓ amplitudes of compound muscle action potential (50%)</li> </ul>		
Key study findings and message	Symptoms may be due to direct viral pathogenicity		Symptoms likely due to critical illness polyneuropathy and/or myopathy	<ul style="list-style-type: none"> <li>Symptoms likely due to critical illness polyneuropathy and/or myopathy, cannot exclude direct viral attack</li> <li>Strokes due to hypercoagulable state due to virus, medication related, vasculitis, shock</li> </ul>	
<b>MERS</b>					
Study	Algahtani et al (2016) N = 2, confirmed cases Case report, review		Kim et al (2017) N = 23, confirmed cases Retrospective study		
Clinical features	<ul style="list-style-type: none"> <li>Neuropathy</li> <li>Myopathy</li> <li>Confusion</li> <li>Ataxia, dizziness</li> <li>Intracranial hemorrhage</li> </ul>		<ul style="list-style-type: none"> <li>Neurological disturbances – 2-3 weeks after respiratory symptoms</li> <li>Myalgia</li> <li>Headache</li> <li>Confusion</li> <li>Hypersomnolence</li> <li>Weakness</li> <li>Paresthesia</li> <li>Hyporeflexia</li> </ul>		
Key findings on investigations			CSF and nerve conduction studies normal		
Key study findings and message	<ul style="list-style-type: none"> <li>Symptoms may be due to critical illness polyneuropathy and/or myopathy</li> <li>Hemorrhage secondary to DIC, platelet dysfunction</li> </ul>		<ul style="list-style-type: none"> <li>Symptoms may be due to critical illness polyneuropathy and/or myopathy or toxin or viral induced</li> </ul>		
<b>COVID-19</b>					
Study	Mao et al (2020) N = 214, confirmed cases Retrospective study	Filatov et al (2020) N = 1, suspected Case report	Bagheri et al (2020) N = 10069, with olfactory	Poyiadji et al (2020) N = 1, confirmed cases Case report	Helms et al (2020) N = 58, confirmed cases Retrospective study

(continued on next page)

**Table 6. (continued)**

COVID-19					
Clinical features	<ul style="list-style-type: none"> <li>Neurological symptoms: 36.4%</li> <li>CNS symptoms: 24.8%, most common dizziness (16.8%), headache (13.1%)</li> <li>PNS symptoms: 8.9%, most common hypogeusia (5.6%) and hyposmia (5.1%).</li> <li>Skeletal muscle symptoms: 10.7%</li> </ul>	Altered mental status	dysfunction Cross-sectional <ul style="list-style-type: none"> <li>Anosmia/hyposmia (48.23%)</li> <li>Sudden onset in 76.24%</li> <li>Associated hypogeusia in 83.38%</li> <li>Duration: 0-30 days</li> </ul>	Acute necrotizing encephalopathy	<ul style="list-style-type: none"> <li>Agitation (69%)</li> <li>Corticospinal tract signs (67%)</li> <li>Confusion (65%)</li> <li>Dysexecutive syndrome (36%)</li> </ul>
Key findings on investigations	N/A	<ul style="list-style-type: none"> <li>CT Head: no acute changes</li> <li>EEG: bilateral slowing and focal slowing in the left temporal region with sharply countered waves, possible subclinical seizures</li> <li>CSF studies: normal</li> </ul>	N/A	<ul style="list-style-type: none"> <li>CSF unremarkable (not tested for COVID)</li> <li>NCCT Head: symmetric hypoattenuation within the bilateral medial thalami</li> <li>CT angiogram, venogram: normal</li> <li>MRI Brain: hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regions</li> </ul>	Brain MRI: <ul style="list-style-type: none"> <li>Perfusion abnormalities (100% of 11)</li> <li>Leptomeningeal enhancement (62% of 13)</li> <li>Ischemic stroke (23% of 13)</li> </ul> CSF (N = 7): <ul style="list-style-type: none"> <li>Oligoclonal bands (29%)</li> <li>Elevated IgG and protein (14%)</li> <li>Low albumin (57%)</li> <li>Negative RT-PCR in CSF (100%)</li> </ul> EEG (N = 8): Nonspecific
Key study findings and message	<ul style="list-style-type: none"> <li>Acute CVA (5.7%), impaired consciousness (14.8%), skeletal muscle injury (19.3%) more likely in severe disease (<math>P &lt; 0.05</math>, <math>P &lt; 0.001</math>)</li> <li>Patients with CNS symptoms more likely to have lower lymphocyte and platelet counts and higher BUN (<math>P &lt; 0.05</math>, <math>P &lt; 0.01</math>, <math>P &lt; 0.05</math>)</li> <li>Patients with muscle injury more likely to have higher neutrophils, CRP, D-dimer and lower lymphocyte count (<math>P &lt; 0.05</math>, <math>P &lt; 0.001</math>, <math>P &lt; 0.05</math>, <math>P &lt; 0.01</math>)</li> <li>Neurologic symptoms may be due to direct viral pathogenicity via hematogenous or retrograde neuronal spread, immunosuppression, or coagulation disorders</li> </ul>	Can present with encephalopathy acutely or during hospitalization	<ul style="list-style-type: none"> <li>High correlation between reported olfactory symptoms and regional reporting of COVID-19</li> <li>Olfactory symptoms may be due to neuroepithelia injury and damage to olfactory roots.</li> </ul>	Cytokine storm (known in influenza, other viral infections, more common in pediatrics)	Mechanism unknown, may be due to critical illness-related encephalopathy, cytokines, medication-induced or direct viral pathogenicity.

ARDS, acute respiratory distress syndrome; CK, creatine kinase; CNS, central nervous system; CRP, C-reactive protein; CSF, cerebrospinal fluid; CVA, cerebrovascular accident; EEG, electroencephalogram; GTCS, generalized tonic clonic seizures; MERS-CoV, middle east respiratory syndrome coronavirus; MRI, magnetic resonance imaging; NCCT, noncontrast computed tomography; PNS, peripheral nervous system; SARS-COV, severe acute respiratory syndrome coronavirus.

Patients with pre-existing neurological diseases may also have a higher risk for encephalopathy and altered mental status.<sup>41</sup> As many as 36.4% patients have neurological symptoms, and these are seen more commonly in patients with severe disease.<sup>42</sup> Acute cerebrovascular accidents, altered mental status, and myopathy occurred in approximately one-third of patients. In an observational series of 58 COVID-19 positive patients, Helms et al documented confusion and agitation as the most common neurologic symptoms. Corticospinal tract signs were also evident in nearly two-thirds of patients including increased deep tendon reflexes, ankle clonus and bilateral extensor plantar reflexes.<sup>43</sup> One recent case report described acute hemorrhagic necrotizing encephalopathy in a patient with COVID-19 infection.<sup>44</sup> Guillain-Barré syndrome has been observed after the onset of COVID-19 in a few patients presenting with lower-limb weakness and paresthesia as well as facial diplegia and ataxia.<sup>45</sup> Neurological involvement is present in more severely affected patients, and patients with central neurologic symptoms also had severe lymphopenia, thrombocytopenia and uremia.<sup>42</sup> Patients with myopathy have a higher inflammatory response and a higher association with hepatic and renal disease.<sup>42</sup>

Patients who underwent magnetic resonance imaging showed leptomeningeal enhancement with bilateral frontotemporal hypoperfusion.<sup>43</sup> Electroencephalography showed mostly nonspecific changes with findings consistent with encephalopathy.<sup>43</sup> CSF analysis may show oligoclonal bands or elevated IgG levels, however, the significance of these findings is uncertain.

Ocular manifestations of COVID-19 are garnering increasing attention. Animal studies show ACE2 and transmembrane serine protease 2, both established receptors for this virus, are expressed in the conjunctiva, although to a lesser extent than in the kidneys and lungs, and lesser in females.<sup>46</sup> A study reported conjunctivitis in as many as 31.6% patients, and more commonly in patients with severe disease.<sup>47</sup> It has also been reported as the sole initial presentation.<sup>48</sup> SARS CoV-2 has been isolated from conjunctival swabs in patients with ocular symptoms and reportedly detected for as many as 27 days after symptom onset.<sup>49</sup> Interestingly, an animal model has also shown that the conjunctival route may lead to systemic infection as well, but viral replication in the conjunctiva and chances of virus release into the bloodstream are very low.<sup>50</sup>

## MUSCULOCUTANEOUS MANIFESTATIONS

### SARS-CoV

As many as 60% of patients with SARS-CoV had myalgia with up to 30% presenting with muscle weakness and increased creatinine phosphokinase (Table 6).<sup>10,34,117-119</sup> However, there was no statistically significant difference in creatinine phosphokinase levels between SARS-CoV patients with ARDS vs. patients without ARDS.<sup>117</sup> Muscle weakness was typically symmetric and involves truncal and weakness of the proximal limbs and neck muscles

with sparing of the facial and small hand muscles.<sup>119</sup> Muscle atrophy may also be the result of steroid myopathy or critical illness myopathy.<sup>119</sup> A variable degree of focal myofibril necrosis noted postmortem without evidence of viral particles suggests that muscle damage is likely the result of immune-mediated damage.<sup>119</sup> Cutaneous manifestations of SARS-CoV hasn't yet been reported in the literature to the authors' knowledge.

### MERS-CoV

Myositis and muscle atrophy are less prevalent than SARS-CoV.<sup>61,120</sup> Muscle weakness was common in patients with MERS-CoV (Table 6).<sup>114</sup> Pathologic specimens mimic SARS-CoV specimens with myopathy and inflammatory cells in the areas of myofibril atrophy.<sup>61</sup> Similar to SARS-CoV, cutaneous manifestation of MERS-CoV infection is rare and has not been widely reported.

### COVID-19

Myalgia is also a common presenting symptom of COVID-19 infection, and 36% of patients develop muscle pain during their illness (Table 6).<sup>121</sup> High creatinine kinase (CK) levels present in 14% to 33% of patients.<sup>22,41,106,122</sup> Patients with suspected COVID-19 and muscle aches were more likely to have abnormal lung imaging findings.<sup>122</sup> Higher CK levels noted in ICU-level patients in a study compared to non-ICU patients, although it was not a statistically significant finding. Rhabdomyolysis has been reported in patients with COVID-19 with MYO levels >12,000 ug/L and CK levels >11,000 U/L.<sup>123</sup>

The cutaneous manifestations of COVID-19 are not widely known beyond the dermatology community. From a series of 88 patients 20% developed cutaneous manifestations including erythematous rash, widespread urticaria, and chickenpox like vesicles.<sup>124</sup> The most common region involved was the trunk and pruritis was uncommon. Several recent case series have reported a viral exanthem similar to chilblains disease in patients with COVID-19.<sup>125</sup> To date, there has been no correlation between cutaneous manifestations of COVID-19 and disease severity.

## HEMATOLOGY MANIFESTATIONS

### SARS-CoVa

Reactive lymphocytosis and severe lymphopenia (<500 cells/mm<sup>3</sup>) are uncommon in patients with SARS (Table 7).<sup>10,126</sup> Patients with SARS-CoV infection often presented with a normal total leukocyte counts.<sup>126,127</sup> There was no correlation between the degree of leukopenia and disease severity. However, patients with a high initial neutrophil count had worse outcomes.<sup>1</sup> Chng et al reported mild to moderate (<1000 cells/mm<sup>3</sup>) lymphopenia as a common finding in SARS-CoV (70-98% of patients), especially during the first 10 days of illness. Initial hemoglobin levels were often normal but gradually decrease later.<sup>10</sup> Thrombocytopenia was present in up to half of the patients, although platelet count levels

**Table 7.** Musculoskeletal Manifestation of SARS-CoV, MERS-CoV and COVID-19.

<b>SARS (only studies with large study population included)</b>						
Study	Lee et al (2003) N = 138, confirmed cases Retrospective study	Donnelly et al (2003) N = 1425, confirmed cases Retrospective study	Choi et al (2003) N = 267 (227 confirmed cases) Retrospective study	Chen et al (2005) N = 67, confirmed cases Retrospective study	Leung et al (2005) N = 8, probable Clinicopathologic study	Yu et al (2006) N = 121, confirmed cases Retrospective study
Clinical features	Myalgia: 60.9%	Myalgia: 50.8%	Myalgia: 50%	Myalgia/arthritis: 13.4%	N/A	Myalgia: 71%
Key findings on investigations	↑ CK (32.1%)	N/A	N/A	↑ CK (20.9%)	↑ CK	↑CK (26%)
Histopathology	N/A	N/A	N/A	N/A	<ul style="list-style-type: none"> <li>Focal myofiber coagulative necrosis</li> <li>Myofiber atrophy in patients who received steroids</li> <li>No virus detected or cultured</li> </ul>	N/A
Key study findings and message	High peak CK predictive of ICU admission and death (univariate, P = 0.04) (Association with CK on admission had P = 0.06)	Myalgia commonly reported	No significant difference in CK levels in probable and confirmed patients	No difference in reporting of myalgia/arthritis in patients with ARDS vs. without	<ul style="list-style-type: none"> <li>Higher CK associated with more myofiber necrosis</li> <li>Myopathy possibly immune mediated, possible component of steroid and critical illness myopathy</li> </ul>	<ul style="list-style-type: none"> <li>↑CK likely due to myositis as cardiac enzymes normal</li> </ul>
<b>MERS</b>						
Study	Omrani et al (2013) N = 3, confirmed cases Retrospective study		Saad et al (2014) N = 70, confirmed cases Retrospective study	Kim et al (2017) N = 23, confirmed cases Retrospective study		Alsaad et al (2017) N = 1, Clinicopathologic
Signs and symptoms			Myalgia or arthralgia: 20%	Myalgia or arthralgia: 26.9%		N/A
Labs	↑ CK		N/A	Electromyogram in 1 normal		N/A
Histopathology	N/A		N/A	N/A		<ul style="list-style-type: none"> <li>Atrophic and myopathic changes</li> <li>Inflammatory changes in perimysium and endomysium, more in areas of atrophy</li> <li>Viral particles detected in macrophages infiltrating muscles</li> </ul>
Key study findings and message	Mild/asymptomatic cases may contribute to spread more than recognised		Myalgia/arthritis common nonrespiratory symptom	Neuromuscular complications during MERS treatment may be underdiagnosed		<ul style="list-style-type: none"> <li>Muscle atrophy and inflammation</li> <li>Viral particles in muscle</li> </ul>
<b>COVID-19</b>						
Study	Huang et al (2020) N = 41, confirmed cases Retrospective study	Chen et al (2020) N = 99, confirmed cases Retrospective	Wang et al (2020) N = 138, confirmed cases, Retrospective study	Guan et al (2020) N = 1099, confirmed cases Retrospective study	Li et al (2020) N = 1994, confirmed cases Meta-analysis, 10 studies	Zhang et al (2020) N = 645, confirmed cases Retrospective study

(continued on next page)

**Table 7. (continued)**

COVID-19	
Clinical features	Myalgia or fatigue: 44%
Key findings on investigations	Myalgia: 11% ↑ CK (13%) (associated with ↑ myocardial enzymes)
Key study findings and message	No difference in level of CK in ICU and non-ICU patients
	Myalgia: 34.8% ↑ CK
	Myalgia or arthralgia: 14.9% ↑ CK >= 200 U/mL: 13.7%
	Myalgia or fatigue: 35.8% (11-50%) ↑ CK: 13-33%
	Myalgia: 11% ↑ CK
	<ul style="list-style-type: none"> <li>• Muscle ache at admission associated with more severe/critical disease (<math>P = 0.002</math>)</li> <li>• Higher CK in patients with abnormal imaging (<math>P &lt; 0.05</math>)</li> </ul>
	<ul style="list-style-type: none"> <li>• Myalgia or fatigue more commonly reported</li> <li>• 5% case fatality rate overall</li> </ul>
	Muscle ache less commonly reported
	Higher CK in ICU patients ( $P = 0.08$ )
	Muscle ache less commonly reported
ARDS, acute respiratory distress syndrome; CK, creatine kinase; ICU, intensive care unit; MERS-CoV, middle east respiratory syndrome coronavirus; SARS-CoV, severe acute respiratory syndrome coronavirus.	

<100,000 cells/mm<sup>3</sup> are rare, and they usually normalized later.<sup>128</sup> Prolonged activated partial thromboplastin time and elevated D-dimer levels were also common abnormalities (63% and 45%, respectively).<sup>10</sup>

The pathogenesis of lymphopenia and thrombocytopenia in SARS has been controversial. In addition to traditional theories, vascular adhesion molecule-1, ligand and severe cytokine storm may play a vital role.<sup>129,130</sup> Thrombocytopenia could be due to the result of interplay between autoantibodies, immune complexes, increased consumption and decreased production of platelets.<sup>128</sup>

**MERS-CoV**

Most patients present with a normal total leukocyte count.<sup>17</sup> One-third of the patients may present with lymphopenia of <1,500 cells/mm<sup>3</sup> and severely low levels during the early stage of the illness 600 cells/mm<sup>3</sup> or less (Table 7).<sup>16,17</sup> Hemoglobin levels are usually normal in patients with MERS-CoV.<sup>131</sup> Mild thrombocytopenia was frequently present in critically ill patients with MERS-CoV and indicates poor prognosis.<sup>17,131</sup> Patients with a fatal form had developed DIC.<sup>17,132</sup> However, there is a paucity of studies explaining the pathogenesis.

**COVID-19**

Data regarding the hematologic manifestations of COVID-19 infection are emerging. Patients with severe disease may have higher total white cell counts (Table 7) (median 6100 cells/mm<sup>3</sup>).<sup>20,21</sup> Otherwise, similar to the other novel coronavirus infections, lymphopenia is a frequent finding, is present in a third of patients.<sup>21,121</sup> Hence, lymphopenia may help as a reference index.<sup>121</sup> However, there may not be any differences in lymphocyte counts between mild and severe forms of COVID-19. Neutrophilia may help to predict ICU admissions. Hemoglobin seems to be mostly unaffected by COVID-19 infection. DIC is a rare complication.<sup>21</sup> In general, mild thrombocytopenia is present in one-third of patients.<sup>21</sup> Patients requiring ICU admissions are seen to have higher levels of D-dimer.<sup>14</sup> A meta-analysis of 9 studies showed significantly higher PT and d-dimer levels in patients with more severe disease, indicating the likelihood of DIC or a highly inflammatory state.<sup>56</sup> The incidence of thromboembolic events in these patients is garnering a lot of attention. A study conducted by Llitjos et al found a 69% incidence of thromboembolic events, with a 56% incidence even in patients treated with therapeutic anticoagulation.<sup>57</sup> Increased levels of circulatory cytokines, ferritin, C-reactive protein and procalcitonin also seem to correlate with the severity of the disease.<sup>34,58</sup>

**OBSTETRICS MANIFESTATIONS**

**SARS-CoV**

Although the data are limited for SARS-CoV in pregnancy, evidence suggests poorer clinical outcomes for pregnant women. Reports are available for 12 pregnant women in Hong Kong and 2 in the United States (Table 8).<sup>133</sup> Among



**Table 8.** Hematological manifestations of SARS-CoV, MERS-CoV and COVID-19.

SARS (only studies with large study population included)						
Study	Lee et al (2003) N = 138, confirmed cases Retrospective study	Wong et al (2003) N = 157, confirmed cases Retrospective	Chng et al (2005) N = 185, confirmed cases Retrospective study	Yang et al (2013) Review		
Key findings on investigations	<ul style="list-style-type: none"> <li>Moderate lymphopenia (69.6%), continued to drop</li> <li>Thrombocytopenia on admission (44.8%)</li> <li>↑D-Dimer (45%)</li> <li>Prolonged aPTT(42.8%)</li> <li>Leukopenia on admission (33.9%)</li> <li>Reactive lymphocytes in peripheral blood (15.2%)</li> </ul>	<ul style="list-style-type: none"> <li>Lymphopenia (98%)</li> <li>Neutrophilia (82%)</li> <li>Prolonged aPTT (63%)</li> <li>Hb ↓ by &gt;20g/L (61%)</li> <li>Thrombocytopenia (55%)</li> <li>Thrombocytosis (49%),</li> <li>DIC (2.5%)</li> <li>↓ CD4<sup>+</sup>, CD8<sup>+</sup> cells</li> </ul>	<ul style="list-style-type: none"> <li>Moderate lymphopenia (61.5%, 80.6% at days 5,10)</li> <li>Leukopenia (19.7%, 50%)</li> <li>Severe lymphopenia (9.8, 18.9%)</li> <li>Severe leukopenia (3.3%, after day 5)</li> <li>Thrombocytopenia (2.5%, 6.6% at days 5, 10)</li> <li>Severe neutropenia (1.6%, 5%)</li> <li>Reactive lymphocytes absent</li> </ul> <p>V shaped trend of cell lines:</p> <ul style="list-style-type: none"> <li>Hb nadir: Day 12</li> <li>WBC (ANC) nadir: Day 7 or 8</li> <li>Platelet nadir: Day 6 or 7</li> <li>Prolonged ↓ lymphocytes in ICU group, no recovery by Day 12</li> </ul>	<ul style="list-style-type: none"> <li>Lymphopenia (68-100%)</li> <li>Thrombocytopenia (20-55%)</li> <li>Leukopenia (19.4-64%)</li> <li>Thrombocytosis in recovery with elevated TPO</li> </ul>		
Histopathology	N/A	Lymphopenia in lymphoid organs on postmortem, including splenic white pulp	N/A	N/A		
Key study findings and message	Neutrophilia associated with ICU care or death (P = 0.02)	↓ CD4 <sup>+</sup> , CD8 <sup>+</sup> cells at presentation associated with ICU care or death (P = 0.029, 0.006)	White count and ANC associated with ICU admission (univariate) (P = 0.034, 0.021)	Mechanism of thrombocytopenia: <ul style="list-style-type: none"> <li>Direct viral attack on hematopoietic stem cells and megakaryocytes</li> <li>Immune mediated</li> <li>Secondary to lung damage</li> </ul>		
MERS						
Study	Assiri et al (2013) N = 47, confirmed cases Retrospective study	Arabi et al (2014) N = 12, (11 confirmed cases, 1 suspected) Case series				
Clinical features	Preexisting malignancy (2%)					
Key findings on investigations	<ul style="list-style-type: none"> <li>Thrombocytopenia (36%)</li> <li>Lymphopenia (34%)</li> <li>Lymphocytosis (11%)</li> </ul>	<ul style="list-style-type: none"> <li>Lymphopenia (75%, 92% on presentation, in ICU)</li> <li>Thrombocytopenia (16.6%, 58% on presentation, in ICU)</li> </ul>				
Key study findings and message	Hematological manifestations common, lymphopenia most common	Lymphopenia commonly seen				
COVID-19						
Study	Chen et al (2020) N = 99, confirmed cases Retrospective study	Wang et al (2020) N = 138, confirmed cases Retrospective study	Guan et al (2020) N = 1099, confirmed cases Retrospective study	Li et al (2020) N = 1994, confirmed cases Meta-analysis, 10 studies	Tang et al (2020) N = 449, confirmed cases Prospective study	Zhou et al (2020) N = 191, confirmed cases Retrospective study
Clinical features	N/A	Preexisting malignancy (7.2%)	Preexisting malignancy (0.9%)	N/A	N/A	Preexisting malignancy (1%)
Key findings on investigations	<ul style="list-style-type: none"> <li>↓Hb (51%)</li> <li>Neutrophilia (38%)</li> </ul>	<ul style="list-style-type: none"> <li>Lymphopenia (70.3%),</li> <li>↑PT (58%)</li> </ul>	<ul style="list-style-type: none"> <li>Lymphocytopenia on admission (83.2%)</li> </ul>	<ul style="list-style-type: none"> <li>Lymphocytopenia (64.5%)</li> <li>Leukocytopenia (29.4%)</li> </ul>	<ul style="list-style-type: none"> <li>↑D-dimer</li> </ul>	<ul style="list-style-type: none"> <li>Lymphopenia (40%)</li> <li>↑D-dimer (42%)</li> </ul>

(continued on next page)

Table 8. (continued)

COVID-19	
<ul style="list-style-type: none"> <li>• †D-dimer (36%)</li> <li>• Lymphopenia (35%)</li> <li>• †PT (30%)</li> <li>• Leukocytosis (24%)</li> <li>• †aPTT (16%)</li> <li>• Thrombocytopenia (12%)</li> <li>• Leukopenia (9%)</li> <li>• Thrombocytosis (4%)</li> <li>• †aPTT (6%)</li> <li>• †PT (5%)</li> </ul>	<ul style="list-style-type: none"> <li>• †D-dimer (46.4%)</li> <li>• Thrombocytopenia (36.2%)</li> <li>• Leukopenia (33.7%)</li> <li>• DIC (0.1%)</li> </ul>
<p>Key study findings and message</p> <p>Various hematological abnormalities commonly seen</p>	<ul style="list-style-type: none"> <li>• Leukocytosis, neutrophilia, lymphopenia, †D-dimer more common in ICU patients (<math>P = 0.003</math>, <math>P &lt; 0.001</math>, <math>P = 0.03</math>, <math>P &lt; 0.001</math>)</li> <li>• Lymphopenia worsened with disease severity</li> </ul> <p>More severe derangements in more severe disease</p> <ul style="list-style-type: none"> <li>• Lymphocytopenia and leukocytopenia more common lab abnormalities</li> <li>• Lymphocytopenia may be used as reference index for coronavirus diagnosis</li> </ul> <ul style="list-style-type: none"> <li>• 28-day mortality of heparin users and nonusers similar (<math>P = 0.910</math>)</li> <li>• 28-day mortality of heparin users less than nonusers in patients with SIC scores <math>\geq 4</math> (<math>P = 0.29</math>), or with D-dimer <math>&gt; 6x</math> normal (0.017)</li> </ul> <p>(Comment by Oudkerk et al)</p>

ANC, absolute neutrophil count; aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; Hb, hemoglobin; ICU, intensive care unit; MERS-CoV, middle east respiratory syndrome coronavirus; PT, prothrombin time; SARS-CoV, severe acute respiratory syndrome coronavirus; TPO, thyroperoxidase; WBC, white blood cell count.

the twelve women in Hong Kong, pregnancy did not appear to impact the initial clinical presentation of SARS. Four of the 7 women presenting in the first trimester miscarried, though this finding is confounded by treatment with the purported teratogen Ribavirin in 6 patients. When compared to matched controls ( $n = 10$ ), the rate of ICU admission was significantly higher in the pregnant group (60% vs. 17.5%,  $P = 0.012$ ). Three pregnant women died, whereas no women died in the matched nonpregnant group ( $P = 0.01$ ).<sup>123</sup> Of the 5 women presenting in the second or third trimester of pregnancy, 4 delivered preterm, 1 spontaneously due to preterm labor and 3 iatrogenic due to worsening maternal status.<sup>124</sup>

There was no evidence of transplacental or intrapartum vertical transmission of SARS-CoV (Table 8).<sup>134-136</sup> However, there may be hypoxia-induced placental blood flow alterations, consequent increased placental fibrin deposition, and thrombotic vasculopathy, resulting in intrauterine growth restriction in women who deliver after convalescence.<sup>134,137</sup>

**MERS-CoV**

Pregnant women with symptomatic MERS-CoV infection may be at a higher risk of adverse events. There are 9 reported cases of symptomatic MERS-CoV in pregnant women, and 7 of them required ICU admission, 5 required mechanical ventilation, and 3 died (Table 8).<sup>138</sup> One case report of a term delivery in a recovered patient and another report of a patient delivered preterm while in the active phase of infection showed negative viral testing in the infant.<sup>138,139</sup> There are 2 reported cases of asymptomatic MERS-CoV infection in pregnant women, both identified via contact tracing. One was identified at 6 weeks gestation, and the other at 24 weeks. Both had healthy term deliveries.<sup>140</sup> Based on available epidemiologic data, it is unclear whether pregnant women with MERS-CoV have worse outcomes, though 3 deaths among eleven reported cases are concerning compared to an 8.9% death rate reported in a nonpregnant female population.<sup>141</sup>

**COVID-19**

Unlike SARS-CoV and MER-CoV, the risk of severe COVID-19 disease in the pregnant population compares favorably to the general population.<sup>116</sup> Recently, a World Health Organization mission group studied 147 pregnant women with COVID-19, 65 confirmed and 82 presumed, of whom 8% had severe disease, and 1% were critical with multiorgan failure (Table 8). As the rate of adverse events seemed less compared to the general population (13.8% severe and 6.1% critical), the mission concluded that pregnant women might not be at increased risk.<sup>142</sup> However, this determination may evolve with more data (Table 9)

There are a few case reports and mini case series discussing the late trimester pregnancy and COVID-19. A study on 38 third trimester pregnant women did not show any severe pneumonia requiring mechanical

**Table 9.** Obstetrics and gynecology manifestations of SARS-CoV, MERS-CoV and COVID-19.

SARS (only studies with large study population included)	
Study	Robertson et al (2004) N = 1, confirmed cases (19 weeks) Case report
Clinical features	Healthy infant at term via C-section (due to placenta previa)
Key findings on investigations	N/A
Histopathology	N/A
Key study findings and message	Healthy mother and infant, no vertical transmission
Study	Wong et al (2004) N = 12, confirmed cases Retrospective study
Clinical features	<ul style="list-style-type: none"> <li>Spontaneous miscarriage (57% in first trimester pregnancies (confounded by treatment with Ribavirin))</li> <li>Preterm delivery (80%) in &gt;24 weeks gestation</li> <li>IUGR (16.6%)</li> </ul>
Key findings on investigations	Newborns tested negative for SARS
Histopathology	N/A
Key study findings and message	No perinatal SARS infection
Study	Lam et al (2004) N = 10 pregnant, 40 nonpregnant confirmed cases Case-control study
Clinical features	<ul style="list-style-type: none"> <li>ICU admission: 60% (pregnant) vs. 18% (nonpregnant) (<math>P = 0.01</math>)</li> <li>Renal failure: 30% vs. 0 (<math>P = 0.01</math>)</li> <li>Sepsis: 20% vs 0 (<math>P = 0.04</math>)</li> <li>DIC: 20% vs 0 (<math>P = 0.04</math>)</li> <li>Death: 30% vs 0 (<math>P = 0.01</math>)</li> </ul>
Key findings on investigations	↑LDH in pregnant patients ( $P = 0.04$ , $<0.0001$ )
Histopathology	N/A
Key study findings and message	Physiologic pregnancy related changes in immune system and respiratory mechanics
Study	Stockman et al (2004) N = 1, confirmed case (7 weeks) Case report
Clinical features	<ul style="list-style-type: none"> <li>Spontaneous PROM</li> <li>Healthy infant via C-section (due to fetal distress)</li> </ul>
Key findings on investigations	Cord blood, placenta, breast milk negative for antibodies
Histopathology	N/A
Key study findings and message	No vertical transmission Antibody formation may be influenced by gestation at infection
Study	Ng et al (2009) 7 placentas Clinicopathologic study
Clinical features	<ul style="list-style-type: none"> <li>Preterm birth (delivery in acute infection)</li> <li>IUGR, oligohydramnios, SGA (concomitant after third trimester infection)</li> </ul>
Key findings on investigations	N/A
Histopathology	Convalescent, infection in third trimester: Extensive fetal thrombotic vasculopathy (FTV), sharply demarcated areas of necrotic villi
Key study findings and message	FTV possibly due to pro-thrombotic state, induced directly by virus, or hypoxia
<b>MERS</b>	
Study	Alserhi et al (2016) N = 1, confirmed case (32 weeks) Case report
Clinical features	Healthy infant at 32 weeks via C-section
Key findings on investigations	Infant negative for MERS-CoV
Key study findings and message	Younger age, infection in later gestational period and immune response may contribute to successful outcome
Study	Assiri et al (2016) N = 5, confirmed cases (all $\geq 22$ weeks) Case series, retrospective
Clinical features	<ul style="list-style-type: none"> <li>All required ICU</li> <li>1 stillbirth, 1 neonatal death</li> <li>2 patients died</li> </ul>
Key findings on investigations	N/A
Key study findings and message	Infection may be associated with maternal and perinatal death and disease
Study	Jeong et al (2017) N = 1, confirmed case Case report, review
Clinical features	<ul style="list-style-type: none"> <li>Asymptomatic patient</li> <li>Healthy infant at 37 weeks via C-section due to placental abruption</li> </ul>
Key findings on investigations	No neonatal IgG
Key study findings and message	Healthy mother and infant, benign course
Study	Allaraj et al (2019) N = 2, confirmed cases (6 weeks and 24 weeks) Case report, review
Clinical features	<ul style="list-style-type: none"> <li>Asymptomatic patients</li> <li>ICU care (54%)</li> <li>Death (27%) (1 infected in second trimester, 2 in third)</li> <li>Infant death rate: 27%</li> <li>Case fatality rate: 35% (similar to nonpregnant, <math>P = 0.75</math>)</li> </ul>
Key findings on investigations	N/A
Key study findings and message	Case fatality similar to nonpregnant cases
<b>COVID-19</b>	
Study	Chen et al (2020) N = 9, confirmed cases Retrospective study
Clinical features	<ul style="list-style-type: none"> <li>8% severe disease (general: 13.8%)</li> </ul>
Study	Zhu et al (2020) WHO-China Joint Mission (2020) N = 147 pregnant (64 confirmed cases, 82 suspected, 1 asymptomatic)
Clinical features	<ul style="list-style-type: none"> <li>8% severe disease (general: 13.8%)</li> </ul>
Study	Liu et al (2020) N = 13 confirmed cases (2 < 28weeks) Retrospective study
Clinical features	Mothers:
Study	Schwartz (2020) N = 36, confirmed cases Review
Clinical features	No maternal deaths
Study	Chen et al (2020) N = 118, confirmed or suspected Retrospective study
Clinical features	Outcomes: • Live births: 70/7

(continued on next page)

Table 9. (continued)

COVID-19	
<ul style="list-style-type: none"> <li>Similar to other COVID-19 patients, no severe pneumonia or death</li> <li>Fetal distress in 2</li> <li>All live births, no complications</li> </ul>	<ul style="list-style-type: none"> <li>1% critical (general: 1%)</li> </ul>
<ul style="list-style-type: none"> <li>Similar to other COVID-19 patients; Neonates:                             <ul style="list-style-type: none"> <li>Intrauterine distress, PROM</li> <li>4 FT, 6 premature</li> <li>2 SGA, 1 LGA</li> <li>Shortness of breath (6)</li> <li>Fever</li> <li>Vomiting</li> <li>Pneumothorax</li> <li>↑HR</li> </ul> </li> <li>Mothers: Similar to other COVID-19 patients; Neonates:                             <ul style="list-style-type: none"> <li>Intrauterine distress, PROM</li> <li>4 FT, 6 premature</li> <li>2 SGA, 1 LGA</li> <li>Shortness of breath (6)</li> <li>Fever</li> <li>Vomiting</li> <li>Pneumothorax</li> <li>↑HR</li> </ul> </li> <li>Neonates:                             <ul style="list-style-type: none"> <li>Thrombocytopenia with abnormal liver function</li> <li>No vertical transmission detected</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Similar to other COVID-19 patients;                             <ul style="list-style-type: none"> <li>1 asymptomatic</li> <li>7.6% required ICU care (general: 5%)</li> </ul> </li> <li>Neonates:                             <ul style="list-style-type: none"> <li>Preterm labor (46%)</li> <li>C-section (77%)</li> <li>Fetal distress 3/10</li> <li>PROM 1/10</li> <li>Stillbirth 1/10</li> </ul> </li> <li>N/A</li> </ul>
<ul style="list-style-type: none"> <li>Amniotic fluid, cord blood, breastmilk, neonate negative for virus</li> </ul>	N/A
<ul style="list-style-type: none"> <li>No vertical transmission in patients with COVID-19 in late pregnancy</li> </ul>	<ul style="list-style-type: none"> <li>Pregnant women do not appear to be at higher risk</li> </ul>
Key findings on investigations	N/A
Message	<ul style="list-style-type: none"> <li>No increased risk of severe disease in pregnant women.</li> <li>Exacerbation of respiratory symptoms in postpartum period likely related to pathophysiological changes.</li> </ul>

DIC, disseminated intravascular coagulation; FT, full term; Hb, hemoglobin; HR, heart rate; ICU, intensive care unit; IUGR, intrauterine growth restriction; LDH, lactate dehydrogenase; LGA, large for gestational age; MERS-CoV, middle east respiratory syndrome coronavirus; PROM, premature rupture of membranes; SARS-CoV, severe acute respiratory syndrome coronavirus; SGA, small for gestational age.

ventilation or maternal deaths, despite co-morbid conditions. There were also no fetal or neonatal deaths.<sup>143</sup> Another study (13 women in the second and third trimesters) reported 1 ARDS and septic shock case with a stillbirth at 34 weeks of gestation.<sup>144</sup> Other reports on women with gestational ages of 25-39 weeks raise concern for an increased risk of preterm rupture of membranes and preterm delivery.<sup>144-146</sup> However, in contrast, a retrospective study of 16 pregnant women infected with COVID-19 compared with 45 noninfected pregnant women showed no differences in preterm labor or preterm delivery, though the youngest gestational age included was only 35 weeks. Also, there was no difference in birth weight between the 2 groups.<sup>143</sup> Pathophysiology in obstetric patients could be due to naturally suppressed cell-mediated immunity and physiologic respiratory changes.<sup>133</sup> A noteworthy observation by Abbas et al has been an increasing incidence of hydatiform moles with the onset of the pandemic. The majority of these cases were primigravidae without other risk factors. They suggest an immune mediated mechanism triggered by the virus and recommend COVID testing in all women with hydatiform moles.<sup>65</sup>

Currently, there is no evidence of vertical transmission of COVID-19, as confirmed by negative viral PCR in 30 neonates.<sup>143</sup> One study of 6 women showed no detectable virus in amniotic fluid, cord blood and breastmilk, nor on a neonatal throat swab.<sup>146</sup> There is a paucity of data regarding COVID-19 infection in the first and second trimesters.

A study investigating the possibility of sexual transmission of COVID-19 found no virus in the vaginal discharge of 35 COVID-19-infected nonpregnant patients, possibly due to the lack of ACE2 expression in the vagina.<sup>147</sup>

CONCLUSIONS

The current COVID-19 pandemic is the third major global illness due to a novel coronavirus. Understanding COVID-19 along with the other known novel CoVs places the newest coronavirus in context. We presented the similarities and differences in pathogenesis, manifestations and outcomes with respect to a spectrum of extrapulmonary organ systems. Increasing knowledge about COVID-19 literature will aid in earlier recognition and more effective therapy.

REFERENCES

- University. JH: corona virus COVID-19 global cases. Centers for Systems Science and Engineering (CSSE)
- Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. *Respirology*. 2018;23(2):130-137.
- Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. *Am J Pathol*. 2007;170(4):1136-1147.
- Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med*. 2012;367(19):1814-1820.
- Kupferschmidt K. Emerging diseases. Researchers scramble to understand camel connection to MERS. *Science*. 2013;341(6147):702.

6. **Garout MA, Jokhdar HAA, Aljhdali IA, et al.** Mortality rate of ICU patients with the Middle East respiratory syndrome - coronavirus infection at king fahad hospital, Jeddah, Saudi Arabia. *Cent Eur J Public Health.* 2018;26(2):87–91.
7. **Almekhlafi GA, Albarrak MM, Mandourah Y, et al.** Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. *Critical Care.* 2016;20(1):123.
8. **Liu CL, Lu YT, Peng MJ, et al.** Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever. *Chest.* 2004;126(2):509–517.
9. **Lien TC, Sung CS, Lee CH, et al.** Characteristic features and outcomes of severe acute respiratory syndrome found in severe acute respiratory syndrome intensive care unit patients. *J Crit Care.* 2008;23(4):557–564.
10. **Lee N, Hui D, Wu A, et al.** A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med.* 2003;348(20):1986–1994.
11. **Srikantiah P, Charles MD, Reagan S.** SARS clinical features, United States, 2003. *Emerg Infect Dis.* 2005;11(1):135–138.
12. **Lam CW, Chan MH, Wong CK.** Severe acute respiratory syndrome: clinical and laboratory manifestations. *Clin Biochem Rev.* 2004;25(2):121–132.
13. **Lang ZW, Zhang LJ, Zhang SJ, et al.** A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). *Pathology.* 2003;35(6):526–531.
14. **Nicholls J, Peiris M.** Good ACE, bad ACE do battle in lung injury, SARS. *Nat Med.* 2005;11(8):821–822.
15. **Gralinski LE, Bankhead 3rd A, Jeng S, et al.** Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. *mBio.* 2013;4(4):e00271-13.
16. **Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, et al.** Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis.* 2013;13(9):752–761.
17. **Arabi YM, Arifi AA, Balkhy HH, et al.** Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. *Ann Intern Med.* 2014;160(6):389–397.
18. **Al-Tawfiq JA, Momattin H, Dib J, et al.** Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. *Int J Infect Dis.* 2014;20:42–46.
19. **Cong Y, Hart BJ, Gross R, et al.** MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. *PLoS One.* 2018;13(3):e0194868.
20. **Wang D, Hu B, Hu C, et al.** Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–1069.
21. **Guan WJ, Ni ZY, Hu Y, et al.** Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020;382:1708–1720. <https://doi.org/10.1056/NEJMoa2002032>.
22. **Huang C, Wang Y, Li X, et al.** Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet.* 2020;395(10223):497–506.
23. **Goyal P, Choi JJ, Pinheiro LC, et al.** Clinical characteristics of Covid-19 in New York City. *N Engl J Med.* 2020; NEJMc2010419. <https://doi.org/10.1056/NEJMc2010419>. [Epub ahead of print].
24. **Zhang H, Zhou P, Wei Y, et al.** Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. *Ann Intern Med.* 2020;M20-0533. <https://doi.org/10.7326/M20-0533>.
25. **Zhou F, Yu T, Du R, et al.** Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet.* 2020;395(10229):1054–1062.
26. **Tang N, Bai H, Chen X, et al.** Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemostasis.* 2020;18:1094–1099.
27. **Conti P, Ronconi G, Caraffa A.** Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents.* 2020;34(2):1. <https://doi.org/10.23812/CONTI-E>. [Epub ahead of print].
28. **Fu Y, Cheng Y, Wu Y.** Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. *Viral Sin.* 2020;1–6. <https://doi.org/10.1007/s12250-020-00207-4>. [Epub ahead of print].
29. **Battle D, Wysocki J, Satchell K.** Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? *Clin Sci (Lond).* 2020;134(5):543–545.
30. **Hanff TC, Harhay MO, Brown TS.** Is There an association between COVID-19 mortality and the renin-angiotensin system—a call for epidemiologic investigations. *Clin Infect Dis.* 2020;ciaa329. <https://doi.org/10.1093/cid/ciaa329>. [Epub ahead of print].
31. **Qiu Y, Zhao YB, Wang Q, et al.** Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. *Microbes Infect.* 2020;S1286-4579(20)30049-6. <https://doi.org/10.1016/j.micinf.2020.03.003>. [Epub ahead of print].
32. **Walls AC, Park YJ, Tortorici MA.** Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell.* 2020;181(2):281–292.e6. <https://doi.org/10.1016/j.cell.2020.02.058>.
33. **Zhang W, Zhao Y, Zhang F, et al.** The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China. *Clin Immunol.* 2020;214:108393-108393.
34. **Yu CM, Wong RS, Wu EB, et al.** Cardiovascular complications of severe acute respiratory syndrome. *Postgrad Med J.* 2006;82(964):140–144.
35. **Pan SF, Zhang HY, Li CS, et al.** Cardiac arrest in severe acute respiratory syndrome: analysis of 15 cases. *Zhonghua Jie He He Hu Xi Za Zhi.* 2003;26(10):602–605.
36. **Li SS, Cheng CW, Fu CL, et al.** Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. *Circulation.* 2003;108(15):1798–1803.
37. **Booth CM, Matukas LM, Tomlinson GA, et al.** Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. *JAMA.* 2003;289(21):2801–2809.
38. **Chen J, Zhang HT, Xie YQ, et al.** Morphological study of severe acute respiratory syndrome (SARS). *Zhonghua Bing Li Xue Za Zhi.* 2003;32(6):516–520.
39. **Ding Y, He L, Zhang Q, et al.** Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. *J Pathol.* 2004;203(2):622–630.
40. **Chong PY, Chui P, Ling AE, et al.** Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. *Arch Pathol Lab Med.* 2004;128(2):195–204.
41. **Guan YJ, Tang XP, Yin CB, et al.** Study on the myocardial injury in patients with severe acute respiratory syndrome. *Zhonghua Nei Ke Za Zhi.* 2003;42(7):458–460.
42. **Wu Q, Zhou L, Sun X, et al.** Altered lipid metabolism in recovered SARS patients twelve years after infection. *Sci Rep.* 2017;7(1):9110.
43. **Alhogbani T.** Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. *Ann Saudi Med.* 2016;36(1):78–80.
44. **Vaduganathan M, Vardeny O, Michel T, et al.** Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. *N Engl J Med.* 2020;382:1653–1659. <https://doi.org/10.1056/NEJMsr2005760>.
45. **Zheng YY, Ma YT, Zhang JY, et al.** COVID-19 and the cardiovascular system. *Nat Rev Cardiol.* 2020;17:259–260.
46. **Bhatraju PK, Ghassemieh BJ, Nichols M, et al.** Covid-19 in critically ill patients in the seattle region - case series. *N Engl J Med.* 2020; 382:2012–2022. <https://doi.org/10.1056/NEJMoa2004500>.
47. **Ruan Q, Yang K, Wang W, et al.** Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med.* 2020;46(5):846–848. <https://doi.org/10.1007/s00134-020-05991-x>.
48. **Long B, Brady WJ, Koyfman A, et al.** Cardiovascular complications in COVID-19. *Am J Emerg Med.* 2020; S0735-6757(20)30277-1. <https://doi.org/10.1016/j.ajem.2020.04.048>. [Epub ahead of print].
49. **Fried JA, Ramasubbu K, Bhatt R, et al.** The variety of cardiovascular presentations of COVID-19. *Circulation.* 2020;141:1930–1936.
50. **Bangalore S, Sharma A, Slotwiner A, et al.** ST-segment elevation in patients with Covid-19 — a case series. *N Engl J Med.* 2020;



- NEJMc2009020. <https://doi.org/10.1056/NEJMc2009020>. [Epub ahead of print].
51. **Wong CK, Lam CW, Wu AK, et al.** Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol.* 2004;136(1):95–103.
  52. **Xiong TY, Redwood S, Prendergast B.** Coronaviruses and the cardiovascular system: acute and long-term implications. *Eur Heart J.* 2020;41(19):1798–1800. <https://doi.org/10.1093/eurheartj/ehaa231>.
  53. **Chau TN, Lee KC, Yao H, et al.** SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. *Hepatology.* 2004;39(2):302–310.
  54. **Hamming I, Timens W, Bulthuis ML, et al.** Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. a first step in understanding SARS pathogenesis. *J Pathol.* 2004;203(2):631–637.
  55. **Xu L, Liu J, Lu M, et al.** Liver injury during highly pathogenic human coronavirus infections. *Liver Int.* 2020;40(5):998–1004. <https://doi.org/10.1111/liv.14435>.
  56. **Duan XF, Liu Z, Hao R, et al.** The dynamic change of liver injury in patients with severe acute respiratory syndrome. *Zhonghua Gan Zang Bing Za Zhi.* 2004;12(7):439.
  57. **Yang Z, Xu M, Yi JQ, et al.** Clinical characteristics and mechanism of liver damage in patients with severe acute respiratory syndrome. *Hepatobiliary Pancreat Dis Int.* 2005;4(1):60–63.
  58. **Yang JK, Lin SS, Ji XJ, et al.** Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. *Acta Diabetol.* 2010;47(3):193–199.
  59. **Al-Hameed F, Wahla AS, Siddiqui S, et al.** Characteristics and outcomes of Middle East respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. *J Intensive Care Med.* 2016;31(5):344–348.
  60. **Saad M, Omrani AS, Baig K, et al.** Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. *Int J Infect Dis.* 2014;29:301–306.
  61. **Alsaad KO, Hajeer AH, Al Balwi M, et al.** Histopathology of middle east respiratory syndrome coronavirus (MERS-CoV) infection - clinicopathological and ultrastructural study. *Histopathology.* 2018;72(3):516–524.
  62. **Boonacker E, Van Noorden CJ.** The multifunctional or moonlighting protein CD26/DPPIV. *Eur J Cell Biol.* 2003;82(2):53–73.
  63. **Boonacker EP, Wierenga EA, Smits HH, et al.** CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry. *J Histochem Cytochem.* 2002;50(9):1169–1177.
  64. **Zhao G, Jiang Y, Qiu H, et al.** Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. *PLoS One.* 2015;10(12):e0145561.
  65. **Mahallawi WH, Khabour OF, Zhang Q, et al.** MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. *Cytokine.* 2018;104:8–13.
  66. **Fan Z, Chen L, Li J, et al.** Clinical features of COVID-19 related liver damage. *Clin Gastroenterol Hepatol.* 2020;18:1561–1566. <https://doi.org/10.1016/j.cgh.2020.04.002>.
  67. **Chai X, Hu L, Zhang Y, et al.** Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. *bioRxiv* [Preprint]. February 4, 2020. <https://doi.org/10.1101/2020.02.03.931766>.
  68. **Leung WK, To KF, Chan PK, et al.** Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. *Gastroenterology.* 2003;125(4):1011–1017.
  69. **Kwan AC, Chau TN, Tong WL, et al.** Severe acute respiratory syndrome-related diarrhea. *J Gastroenterol Hepatol.* 2005;20(4):606–610.
  70. **Peiris JS, Chu CM, Cheng VC, et al.** Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet.* 2003;361(9371):1767–1772.
  71. **Donnelly CA, Ghani AC, Leung GM, et al.** Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. *Lancet.* 2003;361(9371):1761–1766.
  72. **Shi X, Gong E, Gao D, et al.** Severe acute respiratory syndrome associated coronavirus is detected in intestinal tissues of fatal cases. *Am J Gastroenterol.* 2005;100(1):169–176.
  73. **Sampathkumar P, Temesgen Z, Smith TF, et al.** SARS: epidemiology, clinical presentation, management, and infection control measures. *Mayo Clin Proc.* 2003;78(7):882–890.
  74. **Wang WK, Chen SY, Liu IJ, et al.** Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis. *Emerg Infect Dis.* 2004;10(7):1213–1219.
  75. **Choi KW, Chau TN, Tsang O, et al.** Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. *Ann Intern Med.* 2003;139(9):715–723.
  76. **Xu D, Zhang Z, Jin L, et al.** Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. *Eur J Clin Microbiol Infect Dis.* 2005;24(3):165–171.
  77. **Who Mers-Cov Research G.** State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans. *PLoS Curr.* 2013;5: ecurrents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8. <https://doi.org/10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8>.
  78. **Bak SL, Jun KI, Jung J, et al.** An atypical case of middle east respiratory syndrome in a returning traveler to Korea from Kuwait, 2018. *J Korean Med Sci.* 2018;33(53):e348.
  79. **Al-Abdely HM, Midgley CM, Alkhamis AM, et al.** Middle East respiratory syndrome coronavirus infection dynamics and antibody responses among clinically diverse patients, Saudi Arabia. *Emerg Infect Dis.* 2019;25(4):753–766.
  80. **Alenazi TH, Al Arbash H, El-Saed A.** Identified transmission dynamics of Middle East respiratory syndrome coronavirus infection during an outbreak: implications of an overcrowded emergency department. *Clin Infect Dis.* 2017;65(4):675–679.
  81. **Corman VM, Albarak AM, Omrani AS, et al.** Viral shedding and antibody response in 37 patients with middle east respiratory syndrome coronavirus infection. *Clin Infect Dis.* 2016;62(4):477–483.
  82. **Zhou J, Li C, Zhao G, et al.** Human intestinal tract serves as an alternative infection route for middle east respiratory syndrome coronavirus. *Sci Adv.* 2017;3(11):eaao4966.
  83. **Killerby ME, Biggs HM, Midgley CM, et al.** Middle east respiratory syndrome coronavirus transmission. *Emerg Infect Dis.* 2020;26(2):191–198.
  84. **Pan L, Mu M, Yang P, et al.** Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *Am J Gastroenterol.* 2020;115(5):766–773. <https://doi.org/10.14309/ajg.0000000000000620>.
  85. **Gu J, Han B, Wang J.** COVID-19: gastrointestinal manifestations and potential fecal-oral transmission. *Gastroenterology.* 2020;158(6):1518–1519. <https://doi.org/10.1053/j.gastro.2020.02.054>.
  86. **Xie C, Jiang L, Huang G, et al.** Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. *Int J Infect Dis.* 2020;93:264–267.
  87. **Wu Y, Guo C, Tang L, et al.** Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol.* 2020;5(5):434–435. [https://doi.org/10.1016/S2468-1253\(20\)30083-2](https://doi.org/10.1016/S2468-1253(20)30083-2).
  88. **Tian Y, Rong L, Nian W, et al.** Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. *Aliment Pharmacol Ther.* 2020;51(9):843–851.
  89. **Lai KN, Tsang KW, Seto WH, et al.** Clinical, laboratory, and radiologic manifestation of SARS. *Curr Infect Dis Rep.* 2004;6(3):213–219.
  90. **National Taiwan University College of MHuang JW, Chen KY, et al.** Acute renal failure in patients with severe acute respiratory syndrome. *J Formos Med Assoc.* 2005;104(12):891–896.
  91. **Chu KH, Tsang WK, Tang CS, et al.** Acute renal impairment in coronavirus-associated severe acute respiratory syndrome. *Kidney Int.* 2005; 67(2):698–705.
  92. **Naicker S, Yang CW, Hwang SJ, et al.** The Novel Coronavirus 2019 epidemic and kidneys. *Kidney Int.* 2020;97(5):824–828. <https://doi.org/10.1016/j.kint.2020.03.001>.

93. **Wu VC, Hsueh PR, Lin WC, et al.** Acute renal failure in SARS patients: more than rhabdomyolysis. *Nephrol Dial Transplant.* 2004;19(12):3180–3182.
94. **Zou Z, Yang Y, Chen J, et al.** Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases. *Clin Infect Dis.* 2004;38(4):483–489.
95. **Wu VC, Huang JW, Hsueh PR, et al.** Renal hypouricemia is an ominous sign in patients with severe acute respiratory syndrome. *Am J Kidney Dis.* 2005;45(1):88–95.
96. **Kwan BC, Leung CB, Szeto CC, et al.** Severe acute respiratory syndrome in dialysis patients. *J Am Soc Nephrol.* 2004;15(7):1883–1888.
97. **Tang HL, Cheuk A, Chu KH, et al.** Severe acute respiratory syndrome in haemodialysis patients: a report of two cases. *Nephrol Dial Transplant.* 2003;18(10):2178–2181.
98. **Chan KH, Poon LL, Cheng VC, et al.** Detection of SARS coronavirus in patients with suspected SARS. *Emerg Infect Dis.* 2004;10(2):294–299.
99. **Xu J, Qi L, Chi X, et al.** Orchitis: a complication of severe acute respiratory syndrome (SARS). *Biol Reprod.* 2006;74(2):410–416.
100. **Raj VS, Mou H, Smits SL, et al.** Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. *Nature.* 2013;495(7440):251–254.
101. **Cha RH, Joh JS, Jeong I, et al.** Critical care team of national medical C: renal complications and their prognosis in Korean patients with middle east respiratory syndrome-coronavirus from the central MERS-CoV designated hospital. *J Korean Med Sci.* 2015;30(12):1807–1814.
102. **Alqahatani FY, Aleanizy FS, Ali El Hadi Mohamed R, et al.** Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. *Epidemiol Infect.* 2018;1–5.
103. **Yeung ML, Yao Y, Jia L, et al.** MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2. *Nat Microbiol.* 2016;1:16004.
104. **Volunteers A-n, Li Z, Wu M, et al.** Caution on kidney dysfunctions of 2019-nCoV patients. *medRxiv [Preprint].* March 27, 2020. <https://doi.org/10.1101/2020.02.08.200212>.
105. **Cheng Y, Luo R, Wang K, et al.** Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int.* 2020;97(5):829–838. <https://doi.org/10.1016/j.kint.2020.03.005>.
106. **Chen N, Zhou M, Dong X, et al.** Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020;395(10223):507–513.
107. **Zhou F, Yu T, Du R, et al.** Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054–1062. [https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3).
108. **Wang W, Xu Y, Gao R, et al.** Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA.* 2020;323(18):1843–1844. <https://doi.org/10.1001/jama.2020.3786>.
109. **Fan C, Li K, Ding Y, et al.** ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection. *medRxiv [Preprint].* February 13, 2020. <https://doi.org/10.1101/2020.02.12.20022418>.
110. **Tsai LK, Hsieh ST, Chang YC.** Neurological manifestations in severe acute respiratory syndrome. *Acta Neurol Taiwan.* 2005;14(3):113–119.
111. **Hung EC, Chim SS, Chan PK, et al.** Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. *Clin Chem.* 2003;49(12):2108–2109.
112. **Lau KK, Yu WC, Chu CM, et al.** Possible central nervous system infection by SARS coronavirus. *Emerg Infect Dis.* 2004;10(2):342–344.
113. **Tsai LK, Hsieh ST, Chao CC, et al.** Neuromuscular disorders in severe acute respiratory syndrome. *Arch Neurol.* 2004;61(11):1669–1673.
114. **Kim JE, Heo JH, Kim HO, et al.** Neurological complications during treatment of middle east respiratory syndrome. *J Clin Neurol.* 2017;13(3):227–233.
115. **Alqahatani H, Subahi A, Shirah B.** Neurological complications of Middle East respiratory syndrome coronavirus: a report of two cases and review of the literature. *Case Rep Neurol Med.* 2016;2016: 3502683.
116. **Toscano G, Palmerini F, Ravaglia S, et al.** Guillain–barré syndrome associated with SARS-CoV-2. *N Engl J Med.* 2020;NEJMc2009191. <https://doi.org/10.1056/NEJMc2009191>. [Epub ahead of print].
117. **Chen CY, Lee CH, Liu CY, et al.** Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome. *J Chin Med Assoc.* 2005;68(1):4–10.
118. **Omrani AS, Matin MA, Haddad Q, et al.** A family cluster of middle east respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. *Int J Infect Dis.* 2013;17(9):e668–e672.
119. **Leung TW, Wong KS, Hui AC.** Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. *Arch Neurol.* 2005;62(7):1113–1117.
120. **Choi JY.** An outbreak of middle east respiratory syndrome coronavirus infection in South Korea, 2015. *Yonsei Med J.* 2015;56(5):1174–1176.
121. **Li LQ, Huang T, Wang YQ, et al.** 2019 novel coronavirus patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *J Med Virol.* 2020. <https://doi.org/10.1002/jmv.25757>. [Epub ahead of print].
122. **Zheng X, Cai H, Hu J, et al.** Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings. *Int J Infect Dis.* 2020;94:81–87.
123. **Min J, Qiaoxia T.** Rhabdomyolysis as potential late complication associated with COVID-19. *Emerg Infect Dis J.* 2020;26(7).
124. **Recalcati S.** Cutaneous manifestations in COVID-19: a first perspective. *J Eur Acad Dermatol Venereol.* 2020. <https://doi.org/10.1016/j.jaad.2020.03.036>.
125. **Alramthan A, Aldaraji W.** Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East. *Clin Exp Dermatol.* 2020. <https://doi.org/10.1111/ced.14243>. [Epub ahead of print].
126. **Chng WJ, Lai HC, Earnest A, et al.** Haematological parameters in severe acute respiratory syndrome. *Clin Lab Haematol.* 2005;27(1):15–20.
127. **Hui DS, Wong PC, Wang C.** SARS: clinical features and diagnosis. *Respirology.* 2003;8(Suppl):S20–S24.
128. **Yang M, Ng MH, Li CK.** Thrombocytopenia in patients with severe acute respiratory syndrome (review). *Hematology.* 2005;10(2):101–105.
129. **Chen RF, Chang JC, Yeh WT, et al.** Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS). *Microbes Infect.* 2006;8(1):122–127.
130. **Chan PK, Chen GG.** Mechanisms of lymphocyte loss in SARS coronavirus infection. *Hong Kong Med J.* 2008;14(Suppl 4):21–26.
131. **Al-Abdallat MM, Payne DC, Alqasrawi S, et al.** Hospital-associated outbreak of middle east respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. *Clin Infect Dis.* 2014;59(9):1225–1233.
132. **Singh SK.** Middle East respiratory syndrome virus pathogenesis. *Semin Respir Crit Care Med.* 2016;37(4):572–577.
133. **Lam CM, Wong SF, Leung TN, et al.** A case-controlled study comparing clinical course and outcomes of pregnant and non-pregnant women with severe acute respiratory syndrome. *BJOG.* 2004;111(8):771–774.
134. **Wong SF, Chow KM, Leung TN, et al.** Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. *Am J Obstet Gynecol.* 2004;191(1):292–297.
135. **Stockman LJ, Lowther SA, Coy K, et al.** SARS during pregnancy, United States. *Emerg Infect Dis.* 2004;10(9):1689–1690.
136. **Robertson CA, Lowther SA, Birch T, et al.** SARS and pregnancy: a case report. *Emerg Infect Dis.* 2004;10(2):345–348.
137. **Ng WF, Wong SF, Lam A, et al.** The placentas of patients with severe acute respiratory syndrome: a pathophysiological evaluation. *Pathology.* 2006;38(3):210–218.
138. **Jeong SY, Sung SI, Sung JH, et al.** MERS-CoV infection in a pregnant woman in Korea. *J Korean Med Sci.* 2017;32(10):1717–1720.
139. **Alserehi H, Wali G, Alshukairi A, et al.** Impact of middle east respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. *BMC Infect Dis.* 2016;16:105.
140. **Alfaraj SH, Al-Tawfiq JA, Memish ZA.** Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: report of two cases & review of the literature. *J Microbiol Immunol Infect.* 2019;52(3):501–503.



141. **Assiri A, Abedi GR, Al Masri M, et al.** Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. *Clin Infect Dis.* 2016;63(7):951–953.
142. Organization WH. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). 2020. Available at: <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf>
143. **Schwartz DA.** An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. *Arch Pathol Lab Med.* 2020. [In Press]. <https://doi.org/10.5858/arpa.2020-0901-SA>.
144. **Liu Y, Chen H, Tang K, et al.** Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy. *J Infect.* 2020. <https://doi.org/10.1016/j.jinf.2020.02.028>. [Epub ahead of print].
145. **Zhu H, Wang L, Fang C, et al.** Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia. *Transl Pediatr.* 2020;9(1):51–60.
146. **Chen H, Guo J, Wang C, et al.** Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *Lancet.* 2020;395(10226):809–815.
147. **Cui P, Chen Z, Wang T, et al.** Clinical features and sexual transmission potential of SARS-CoV-2 infected female patients: a descriptive study in Wuhan, China. *medRxiv [Preprint].* March 3, 2020. <https://doi.org/10.1101/2020.02.26.20028225>.

Submitted May 1, 2020; accepted May 1, 2020.

Correspondence: Baskaran Sundaram, MD, Department of Radiology, Thomas Jefferson University, 132 S 10th St; Suite 861, Main Bldg., Philadelphia, PA 19107. (E-mail: [Baskaran.sundaram@jefferson.edu](mailto:Baskaran.sundaram@jefferson.edu)).